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Red blood cells
Aerobic organisms require oxygen for their viability. Through the oxidation of nutrients, 
such organisms generate energy. As organism size and complexity increased through 
evolution, not all the cells of an organism were directly exposed to available oxygen. To 
overcome this problem, vertebrates have evolved a circulatory system that actively delivers 
oxygen to the cells. Red blood cells (RBCs) in the circulating blood are the carriers, taking 
up oxygen in the lungs or gills and delivering it to internal tissues. The actual oxygen-bind-
ing molecule in the red blood cells is hemoglobin, an iron-containing protein that gives 
blood its red colour. One millilitre of human blood contains approximately 5 milliard RBCs 
that have a lifetime of about four months. Aging cells are removed from the circulation and 
destroyed by macrophages in the spleen and liver. To replace them, an adult produces about 
1011 RBCs daily.
Hematopoietic stem cells
All blood cells derive from hematopoietic stem cells (HSCs) that are at the base of a complex 
hematopoietic cell differentiation hierarchy. These stem cells possess a high proliferative 
potential, are self-renewing and remain active over the lifespan of the individual.133,144,159
The incidence of HSCs is very low. In adult bone marrow only 1 to 10 in 100.000 cells 
are estimated to be HSCs.27,95,96 HSCs self-renew by producing daughter cells that retain 
stem cell characteristics. Alternatively, daughter cells divide and differentiate into one of 
the blood lineages. HSCs are pluripotent, which means they can give rise to every type of 
mature blood cell; erythrocytes, neutrophils, basophils, eosinophils, platelets, monocytes, 
macrophages, osteoclasts, and the T and B lymphocytes (Figure 1). Once lineage choices 
are made, progenitors display increasingly limited lineage potentials at each branch point. 
To maintain their multipotentiality, stem cells are thought to have a wide-open chromatin 
structure. This is progressively quenched during the differentiation process, concomitant 
with a progressive restriction of developmental potential.1
Thus, stem cells are a unique cell type in that they can produce more stem cells, as well 
as a population of cells that can undergo further development and/or differentiation.176,177 
Although the model proposes that differentiating cells become more committed after each 
branch point, there is evidence that the loss of developmental potential is reversible.155 In 
addition, a number of recent reports suggest that HSCs from murine bone marrow may be 
more plastic than previously thought. Depending on culture conditions, HSCs can dediffer-
entiate or be reprogrammed, giving rise to non-hematopoietic tissues including neural cells, 
hepatocytes, myocytes, muscle tissue and multiple organ tissues.84,85,130 However, the plas-
ticity of HSCs is still under question, since tissue-specific stem cells could be mislabelled as 
HSCs and contribute to non-hematopoietic cell tissues. Furthermore, two reports challenge 
the concept of transdifferentiation by showing the spontaneous fusion of mouse bone mar-
row or brain cells with ES cells after which they take on the ES cell characteristics.204,233
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The clinical importance of HSCs is reflected in the nearly forty years of bone marrow 
transplantations for the treatment of inherited and acquired disorders of the blood system. 
A large amount of clinical and fundamental research has focused on the biology of bone 
marrow and more recently, umbilical cord blood HSCs. Despite these intense efforts, the 
cellular characteristics of HSCs are still poorly described. In experimental mouse models, 
the activity of HSCs is determined by their potential to long-term repopulate irradiated 
adult recipients.144,152 They are generally present in the Sca-1+ c-kit+ CD34+ Lin- population 
of adult bone marrow.106,127,162,198 Sca-1 and c-Kit are expressed on HSCs but also on other 
cell types. Generally, no HSC activity is found in cell populations negative for Sca-1 or c-
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Figure 1. Schematic representation of the hematopoietic hierarchy
The hematopoietic stem cell gives rise to all blood cells. During differentiation, cells loose their 
pluripotent capacity and become progressively more restricted to one of the blood cell lineages. HSC= 
hematopoietic stem cell; HPC= hematopoietic progenitor cell; CMP= common myeloid progenitor; 
CLP= common lymphoid progenitor MEP= myeloid and erythroid progenitor and GMP= granulocyte 
monocyte progenitor. Adapted from Gilbert.73
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Kit. CD34 has proven to be a useful HSC marker mainly in mouse embryos,186 whereas in 
adult mice most HSC activity was found in a CD34- cell population.142 The lineage marker 
negative cell (Lin-) fraction consists of cells negative for a mixture of antibodies that rec-
ognize differentiated cells. Thus, HSCs are enriched by using a combination of antibodies 
recognizing surface markers and such cells are characterized as Sca-1+ c-kit+ Lin- cells. The 
dye rhodamine can be used for further enrichment. Rhodamine stains highly active mito-
chondria.45 Since most HSCs are inactive, they are found in the rhodamine dull fraction.216 
A recent paper demonstrates that endoglin, an ancillary TGF- receptor, is another useful 
marker for HSC enrichment. HSCs were exclusively found in the Endo+ Sca-1+ Lin-/low, but 
not in the Endo- Sca-1+ Lin-/low population. Furthermore, the Endo+ Sca-1+ Rhdull phenotype 
defines an almost pure population of HSCs from mouse bone marrow.40
The bone marrow is established as the principle hematopoietic tissue around birth, be-
ing seeded with HSCs that are generated earlier in the embryo. In the mammalian 
embryo, several tissues serve as reservoirs and/or generators of hematopoietic activity: 
the yolk sac,150 the para-aortic splanchnopleura (PAS),82,83 the aorta-gonad-mesonephros 
(AGM),143,145,152 the placenta,3 the liver,100,113 the spleen and the thymus151 (reviewed by 
Dzierzak et al63). 
The first hematopoietic tissue in the developing mouse is the yolk sac. Around day 7 of 
gestation (E7) extra-embryonic blood islands appear in the yolk sac, from which primi-
tive erythroblasts and endothelial cell differentiate. Primitive erythroblasts enter the newly 
formed vascular system and continue to divide for several days.21 They differentiate within 
the blood stream, accumulating hemoglobin and becoming less basophilic with a progres-
sively condensed nucleus.12,187 At this stage primitive erythrocytes are distinct from the 
definitive erythrocytes found in the adult. The majority of the primitive erythrocytes retain 
their nucleus, whereas definitive erythrocytes enucleate at the end of their differentiation 
program. Primitive cells are bigger and contain about four times the amount of hemoglobin 
found in definitive erythrocytes.199 Moreover, primitive erythrocytes differ in their globin 
gene expression patterns from adult erythrocytes (see ‘β-globin locus’).12,31 It is thought 
that these first differentiated hematopoietic cells are critical for delivering oxygen to the 
rapidly growing embryo and thus, the yolk sac serves as an efficient supplier of these first 
circulating blood cells. 
The PAS/AGM region is the first intra-embryonic hematopoietic tissue. Although it does 
not contain erythropoietic foci, functional hematopoietic assays have indicated the presence 
of hematopoietic stem cells, starting at E10.5 until E13.83,145 These HSCs are exclusively 
and autonomously generated in the AGM at E10/E11, independent of the yolk sac and are 
the first definitive HSCs. Around late E11, they are thought to colonize the fetal liver, giv-
ing rise to all adult hematopoietic lineages including adult erythrocytes.143 Although eryth-
rocytes and hematopoietic progenitors are first found in the fetal liver around E9, these he-
matopoietic cells are thought to be derived from the yolk sac. At E12, the number of HSCs 
in the fetal liver increases dramatically, suggesting that this microenvironment supports the 
expansion of HSCs.65,152 The liver is considered to be the principle hematopoietic tissue dur-
ing the fetal stage of mouse development. Around the time of birth, stem cells from the liver 
are thought to populate the spleen and the bone marrow, which then becomes the major site 
of blood formation throughout adult life.28
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Erythropoiesis
HSCs can differentiate into red blood cells via a differentiation program called eryth-
ropoiesis (see Figure 2). The erythroid differentiation program takes place through a 
series of numerous and distinct cell intermediates, some of which are morphologically 
recognizable and some which require in vitro functional assays to retrospectively be 
identified. Following the HSC, the first slightly differentiated cell in this series is the 
CFU-S (colony forming unit - spleen). In vivo these cells form macroscopic erythroid-
myeloid colonies on the spleens of lethally irradiated recipient mice 9 to 14 days post-
injection. Although CFU-S are still multipotent, these cells have lost their long-term 
repopulation capability. The next more differentiated progenitor in the series is the 
lineage restricted CFU-GEMM (colony forming unit - granulocyte, erythrocyte, mac-
rophage, and megakaryocyte). These cells differentiate in vitro to all erythroid-myeloid 
cell types, but have no lymphoid potential.112 The first erythroid lineage restricted pro-
genitor is the BFU-E (burst-forming unit, erythroid). These cells are named after the 
large in vitro colonies they form in 7-10 days in semi-solid medium under the influence 
of erythropoietin (EPO), interleukin-3 (IL-3) and stem cell factor (SCF). These colo-
nies consist of up to 5000 mature erythrocytes.146 The next erythroid lineage restricted 
progenitor in the series is the CFU-E (colony-forming unit, erythroid). CFU-Es form 
small in vitro colonies (8-64 cells) when cultured for a short time in semi-solid medium 
(3-4 days). When BFU-Es develop into CFU-Es, they lose responsiveness to IL-3 and 
SCF, but remain dependent on EPO.188-190 
CFU-Es produce the first morphologically recognizable differentiated member of the 
erythroid lineage, the pro-erythroblast. From this stage on, the erythroid progenitors 
can be distinguished by microscopic examination because they are smaller than cells at 
earlier stages of differentiation. Around the pro-erythroblast stage, cells become posi-
tive for the TER-119 surface antigen.121 The TER-119 specific antibody is widely used 
to detect this exclusive marker of erythroid lineage cells.
The completion of the erythroid differentiation program in pro-erythroblast cells in-
cludes about four rapid cell divisions.2 First, the size of the nucleus decreases somewhat 
and the cytoplasm becomes more basophilic due to an increase in ribosomes. Hence, 
at this stage the cells are called basophilic erythroblasts. Subsequently, the cells start 
to produce high amounts of hemoglobin. As a result, the cytoplasm attracts both basic 
and eosin stains, and the cells are called polychromatophilic erythroblasts. Eventually, 
the cytoplasm becomes more eosinophilic, and the cells are then called orthochromatic 
erythroblasts. In these last differentiation steps the cells continuously decrease in size. 
Following the expulsion of the nucleus, orthochromatic erythroblasts become reticu-
locytes. Reticulocytes take their name from the reticular networks of polyribosomes 
that are formed at this differentiation stage. Despite the absence of the nucleus, these 
cells still translate globin mRNA into functional protein. As a final differentiation 
step, reticulocytes loose their polyribosomes to become mature red blood cells. These 
erythrocytes are small cells with up to 25% of their cytoplasmic volume taken up by 
hemoglobin. In humans, erythrocytes have a diameter of 7-8 µm and their shape is the 
visually distinct biconcave disk.66 
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Erythropoiesis in vitro
To study erythropoiesis at the molecular level, a reliable in vitro culture system is highly 
desirable. For many years, the colony forming unit assays have been used to study progeni-
tors in the erythroid lineage differentiation hierarchy.200 Single BFU-E cells grow in 7-10 
days in semi-solid medium in the presence of EPO, IL-3 and SCF to large colonies, whereas 
CFU-E cells form smaller colonies in 3-4 days. CFU-Es have lost responsiveness to IL-3 
and SCF.146 These assays are useful for the detection of erythroid cells that have developed 
to the various stages in differentiation. However, the small number of cells and lack of syn-
chronous differentiation does not allow using these cultures for studying molecular events. 
Other differentiation models include erythroid cell lines that have an erythroleukemic ori-
gin. To some extent these cells are useful models to study erythropoiesis, although they do 
have their shortcomings; erythroleukemic cell lines generally fail to efficiently execute the 
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Pro-
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Figure 2. Erythropoiesis
Schematic drawing of the various stages in the erythroid differentiation programme. Vertical direction 
indicates cells in differentiation stages that require in vitro functional assays to retrospectively 
be identified. Horizontal direction indicates cells that are morphologically recognizable. CFU-S= 
colony forming unit – spleen; CFU-GEMM= colony forming unit – granulocyte, erythrocyte, mac-
rophage, and megakaryocyte, BFU-E= burst-forming unit, erythroid and CFU-E= colony-forming 
unit, erythroid
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normal erythroid differentiation program (four to five terminal cell divisions, massive size 
reduction, nuclear condensation and enucleation).2,59,189 A frequently used model to study 
erythropoiesis is the Friend virus murine erythroleukemia (MEL) cell line.77 However, these 
cells do not recapitulate an in vivo-like differentiation program; differentiation is induced 
by non-physiological agents such as dimethyl sulfoxide and hemoglobin levels are much 
lower than found in erythrocytes of peripheral blood. Another erythroid cell line is the J2E 
cell line. These cells were immortalised by transformation of the oncogenes v-myc and 
v-raf. Although they start differentiating in response to the physiological agent EPO, the 
culture continues to proliferate after induction and only half of the cells accumulate hemo-
globin.123 
A highly advantageous approach is to use primary erythroid cells that recapitulate normal 
erythroid differentiation more faithfully. Only recently have the conditions for culturing 
and differentiating large numbers of primary erythroid cells been achieved. A culture 
method was developed in which erythroid cells are strictly dependent on physiological 
agents.220 Primary mouse cells, isolated from fetal livers, proliferate in a serum-free me-
dium under the control of EPO, SCF and dexamethasone (Dex). These proliferating cells 
are characterised as pro-erythroblasts. When exposed to the physiological differentiation 
factors EPO and insulin, in absence of SCF and Dex, the cells undergo synchronously 
an in vivo-like differentiation program. Within approximately two days, they mature 
terminally into enucleated erythrocytes and express stage-specific erythroid genes in 
the expected temporal order.60 In addition to the primary cell cultures, an immortalised 
cell line has been made using this method. Fetal liver cells from mice lacking the tumor 
suppressor gene p53 were maintained under proliferative conditions, leading to the im-
mortalised cell line I/11.220 This cell line behaves similar to primary cells when cultured 
under proliferating conditions; in serum free medium with EPO, SCF and Dex the cells 
proliferate at an erythroid progenitor stage. After changing the proliferation medium with 
differentiation medium, the cells undergo a synchronous differentiation program. This 
differentiation program lasts slightly longer than for the primary cells, as enucleated 
erythrocytes appear after approximately three days.
In our group, yet another culture method has been developed to study erythropoiesis. It is 
called the hanging drop culturing method. This method has been described for a variety of 
cell types, most commonly for the differentiation of T lymphoid progenitors.30 Fetal liver 
cells are resuspended in a medium containing fetal calf serum, EPO, insulin and hemin. 
The cells are cultured in small drops, hanging from the lid of a Petri dish. Cells sink to the 
bottom of the droplet, resulting in a high concentration of cells and the cells are in physical 
contact with each other. Differentiation and enucleation is evaluated on the basis of cell 
size by cytospin- and FACS analysis. The majority of wild type fetal liver cells differentiate 
and enucleate within two to three days (unpublished). This method allows a swift study of 
erythroid differentiation of fetal liver derived progenitors. Possibilities for molecular analy-
sis of these cultures are limited; the small number of cells that are typically used suffices 
e.g. for real time PCR, but not for extensive Western blot analysis. Furthermore, the cells 
are at various differentiation stages at the beginning of an experiment. Synchronisation of 
the cells by culturing them in proliferation medium as described above is therefore advanta-
geous for the study of the cells at various intermediate differentiation stages. 
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Diseases
Hemoglobinopathies are the most prevalent of all human genetic diseases. Most of these 
disorders are caused by mutations or deletions in the genes on the α- or β-globin locus or 
in their regulatory elements. Extensive clinical and fundamental investigations motivated 
by the need to improve therapies for such a large group of patients have contributed to the 
current understanding of globin gene regulation and regulation of gene expression in gen-
eral.170 The two most common hemoglobinopathies are thalassemia and sickle cell anemia. 
Less common is hereditary persistence of fetal hemoglobin (HPFH), which is a condition 
rather than a disease.
Thalassemias
The name ‘thalassemia‘ is derived from the Greek word ‘thalassa’ (‘sea’), because it is well 
recognized that there is a high incidence of people suffering from this hemoglobinopathy 
near the Mediterranean Sea. The curious geographical distribution of thalassemia, as well 
as sickle cell anemia (see below) resembles that of malaria. It was found that heterozygous 
carriers of these diseases appear to have a slightly improved resistance to malaria. A small 
but highly significant degree of protection against malaria may be the result of an acceler-
ated destruction of infected erythrocytes.9 This results in a selective survival advantage, 
explaining why these disorders are maintained at a high frequency in areas where malaria 
used to be endemic.224
Thalassemias are caused by a disturbance in the expression of either the α- or β-globin 
genes. A shortage in α- or β-globin expression causes α- or β-thalassemia respectively. 
Normally the production of the α- and β-globins is in balance and two of both globins join 
to form a tetrameric hemoglobin molecule with a central iron moiety. Because of a reduced 
expression of one of the globins, thalassemia patients have unbalanced quantities of α- and 
β-globin proteins. This leads to the formation of erythrocytes lacking sufficient functional 
hemoglobin and results in anemia. Moreover, the precipitation of the excess of free globin 
chains make the red cells vulnerable to degradation, further contributing to the anemia.206 
The severity of the phenotype can range from mild to lethal anemia, depending on the extent 
of the disturbance between α- and β-globin protein levels. Many deletion- and non-deletion 
type β-thalassemia mutations have been described.47 The deletion type thalassemias usually 
have large segments of the globin gene locus missing, including genes and/or regulatory 
elements. The identification of these segments and correlation with disease phenotype and 
severity has played a role in the discovery of important regulatory elements. For example, 
the genetic characterization of Dutch deletion type β-thalassemia led to the discovery of the 
Locus Control Region. These patients have an intact β-globin gene, including the promoter. 
However, they have a large deletion of DNA upstream of the β-globin gene that contains 
regulatory elements required for its transcription.89,122,202,217
Non-deletion type thalassemias give rise to frameshifts, nonsense mutations, RNA process-
ing mutants or a decrease in transcription of globin genes. Some of these molecular changes 
have led to the identification of important promoter elements, such as the β-globin CACC 
box. This is a binding site for the erythroid-specific transcription factor EKLF. Muta-
tions within the CACC box result in severe down regulation of the β-globin gene expres-
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sion.73,128,161 Apart from the mutations in the EKLF binding site, a variety of other, non-dele-
tion mutations have been described that lead to β-thalassemia.104
The development of therapies for thalassemias is facilitated by the establishment of mouse 
models. Both the adult mouse β-globin genes have been deleted. Heterozygous mice of this 
deletion show characteristics typical for thalassemia, whereas homozygous mice for the 
deletion die of anemia.44,231
Sickle cell anemia
Sickle cell disease is caused by a single base pair mutation in the β-globin gene, resulting 
in a substitution of valine for glutamine at position 6 of the β-globin chain.107 This altera-
tion markedly reduces the solubility of the deoxygenated, but not the oxygenated form of 
hemoglobin. Deoxygenated mutant globins form large polymers and precipitate. This leads 
to deformation of the red blood cells into sickle-shaped cells, which have now lost their 
deformability. Patients have modest to severe anemia and crisis of peripheral tissues. Such 
a crisis is caused by a vicious cycle: vessel blockage (that can be caused by sickled cells) 
leads to a local low oxygen concentration. This results in a transition of more hemoglobin 
into the deoxygenated form, which again causes more sickling, thus resulting in an exten-
sion of the original lesion and necrosis. Although sickle cell anemia was the first hereditary 
disease to be understood at the molecular level, there is still no adequate treatment. The 
establishment of a mouse model for this disease has facilitated the development of thera-
pies. Transgenic mice that express human sickle hemoglobin were mated with mice having 
knockout mutations of the mouse α- and β-globin genes, resulting in mice that express only 
the mutated human hemoglobin.185
Hereditary persistence of fetal hemoglobin
Hereditary persistence of fetal hemoglobin (HPFH) is characterized by the presence of a 
substantially elevated level of fetal hemoglobin in adults. It is considered a condition rather 
than a disease, since the fetal hemoglobin can substitute the adult hemoglobin without clini-
cal consequences. However, HPFH is often found in combination with β-thalassemia or 
sickle cell anemia. The increased levels of fetal hemoglobin ameliorate the clinical course 
of these diseases.50,118,230 Similar to the thalassemias, there are both deletion- and non-dele-
tion types of HPFH. The non-deletion types of HPFH are characterized by the presence 
of point mutations in the promoter regions of the Gγ or Aγ genes, which are thought to 
alter interactions between various transcription factors and the promoter. For instance, in 
transgenic mice it was found that the point mutation found in the Greek non-deletion HPFH 
causes loss of binding of transcription factor GATA1 to the γ-globin promoter, resulting in 
persistence of γ-globin expression.20 A number of deletion types of HPFH are described75 
and studied in mouse models.4,6,116 In most cases, the β-globin gene is deleted, bringing 
distal hypersensitive sites in close proximity of the γ-genes.117
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Chromatin and transcription
The DNA in the nucleus is highly organized72 (Figure 3). It is bound to proteins, together 
called chromatin. In order to fit all the chromatin into the nucleus, it is organized at different 
levels. In the first place, the DNA is wrapped around histones. Each histone forms a sym-
metrical octamer of two of each of the H2A, H2B, H3 and H4 proteins. About 147 bp of 
DNA is wrapped twice around each histone, resulting in a ‘beads on a string’-like structure 
that compacts the DNA five- to ten-fold.124,125 The histones, especially their N-terminal tails, 
are subject to many covalent modifications. These modifications include lysine acetyla-
tions, lysine and arginine methylations, serine phosphorylations, lysine ubiquitinations, 
as well as other modifications about which less is known.19,105,126,137,182,221 Two distinct, but 
non-exclusive models explain the influence on chromosome function by these modifica-
tions. Firstly, nearly all modifications alter the electrostatic charge of the histone, which 
could change the structural properties of the histone or the binding to the DNA. Secondly, 
the modifications might create a special surface that is recognized by specific proteins. 
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Figure 3. Chromatin packing
Various levels of chromatin packing that leads to a highly organised chromosome. 
Adapted from Alberts et al.2
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Therefore, functional complexes can be recruited to their proper sites of action. As a result, 
chromatin can be involved in both activation and repression of gene expression, depending 
on the nature of the complexes attracted.
The space between nucleosomes can vary in length (~10 - 80 bp) and is a binding target for 
histone H1, which is required for the next level of compaction. H1 stabilises a polynu-
cleosome string folded into a compact fibre with a diameter of ~30 nm. This results in 
an approximately 40-fold compaction of the linear DNA.86,207 The chromatin is thought 
to be further organized by non-histone proteins. The resulting chromatin structure is 
roughly divided into two types: euchromatin and heterochromatin (reviewed by Dillon 
and Festenstein57). Heterochromatin stays condensed throughout the cell cycle and is in 
general transcriptionally inactive. Euchromatin undergoes a typical cycle of condensa-
tion and unravelling. It defines more accessible and transcriptionally active portions of 
the genome.
In general, the higher order chromatin structures are associated with gene inactivation. 
Loss of higher order chromatin structure is often detectable by an increase in sensitivity 
to nucleases such as DNAseI. DNA is cut more easily by DNAseI when it is present in an 
open, accessible chromatin structure. Therefore, susceptibility to DNAseI can be used as 
an assay to measure the general accessibility of DNA regions in chromatin. Sensitivity can 
extend over the entire region of a transcribed gene, including regions up- and downstream 
of the genes. This type of general DNAseI sensitivity has been attributed to more common 
chromatin changes caused by the absence of histone H1, the acetylation of histones or 
hypomethylation of DNA sequences.102,115,191,203,219 In addition to sensitivity regions, some 
regions are particularly susceptible to DNAseI digestion and are called hypersensitive sites 
(HS). These HS are reliable indicators of cis-regulatory elements: DNA sequences that 
regulate gene expression such as promoters and enhancers.90
Polymerase II promoters are found immediately upstream of the transcription initiation site. 
They are about 100 bp in length and are the minimal requirement for accurate and efficient 
initiation of transcription of a gene. A number of sequence motifs can be found in most pro-
moters: The TATA box and initiator are often referred to as the core promoter. A third ele-
ment is found in a subset of TATA box-deficient promoters approximately 30 nucleotides 
downstream of the RNA start site and is termed the downstream promoter element (DPE).37 
These elements recruit the basal transcription machinery and determine the precise site of 
transcription initiation. Additional elements are found in promoters, consisting of typical 
recognitions sites such as CCAAT and CACC boxes. Both ubiquitous and specific trans-
acting factors recognize these sites. Many of these trans-acting factors recruit chromatin-
remodelling complexes to the promoter and open up the chromatin.71
Enhancers are cis-regulatory elements with a size that ranges from 50 base pairs to 1.5 kilo 
base pairs, containing binding sites for transcription factors. They are functionally defined 
by their ability to stimulate transcription, independent of their orientation and with some 
flexibility in distance to the promoter.10,25 Enhancers are found up to several kilo bases 
upstream, downstream and within genes. Enhancers cannot initiate transcription by them-
selves, but they cooperate with one or a number of promoters. It appears that this coopera-
tion results in an increase of establishing and maintaining an active transcriptional state, 
rather than increasing the transcription rate.139,222,225
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Like enhancers, Locus Control Regions (LCRs)135 have a strong, transcription-enhancing 
activity on linked genes. However, unlike enhancers, LCRs possess all the properties neces-
sary for opening a chromosome domain and preventing heterochromatinisation at ectopic 
sites. LCRs are defined by their ability to drive high-level expression of linked genes in a 
tissue-specific and copy number-dependent manner. The components of LCRs are hyper-
sensitive to DNAseI in cells that actively transcribe the linked genes. These components 
contain multiple ubiquitous and lineage specific transcription factor-binding sites. An LCR 
was first identified in the human β-globin locus.89 Since then, several others have been iden-
tified and described in a broad spectrum of mammalian gene systems, suggesting that they 
play an important role in the control of tissue-specific eukaryotic gene expression.135
In addition to these cis-regulatory elements, trans-acting factors are necessary for tran-
scription. The central component required for the transcription of the DNA into RNA is 
the enzyme RNA polymerase (RNAP). Eukaryotes contain three highly related enzymes: 
RNAPI, RNAPII and RNAPIII. Each of these enzymes is dedicated to the transcription 
of a specific set of genes. RNAPI recognizes a single promoter structure and transcribes 
only the ribosomal RNA genes.91 The genes transcribed by RNAPIII have in common that 
they are short (< 400 bp) and encode structural or catalytic RNAs, such as transfer RNA 
(tRNA) and small nuclear RNA (snRNA).192 Protein-encoding messenger RNA (mRNA) 
is transcribed by RNAPII. Transcriptional regulation depends on an RNAPII-protein 
complex that consists of numerous proteins.134 General transcription factors (GTFs; e.g. 
TFIID, TFIIB, TFIIF, TFIIE, TFIIH and TFIIA) are necessary for accurate promoter 
recognition and transcriptional initiation. Transcription is preceded by the formation of a 
pre-initiation complex (PIC) that consists of the GTFs, the template DNA and RNAPII. 
The PIC formation starts with the binding of TFIID to the core-promoter elements, usu-
ally a TATA box.87,183 Fine tuning of gene transcription is accomplished by cooperation 
of the RNAPII protein complex with sequence-specific activators (e.g. tissue specific 
transcription factors) and co-regulators (e.g. chromatin modifying- and chromatin remod-
elling complexes).134
Transcription factors
Since basically all cells in an organism have identical genetic information, differences 
between cell types are established through differential regulation of gene expression. Tran-
scription factors play an important role in this regulation. They integrate physiological and 
environmental signals and make a cell respond correctly to these signals by enhancing or 
repressing the expression of particular genes.
A number of domains can be found in transcription factors. One of these is the domain that 
physically interacts with the DNA, usually at promoter and/or enhancer sites. The DNA 
binding domain is one of a number of common structural motifs including zinc-fingers, 
helix-turn-helix, helix-loop-helix and leucine zipper motifs.97,164 The surface of these motifs 
is such that it strongly binds specific DNA sequences. Small differences in the amino acid 
chain can alter the affinity and/or the DNA sequence that they recognize.
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Apart from the DNA binding domain, transcription factors usually contain a separable 
domain that either activates or represses gene transcription.36,148 The activation or repres-
sion is accomplished by binding to proteins or protein complexes. For instance, they can 
bind the basal transcription machinery, recruiting this complex to the correct transcription 
initiation site.154 They can also bind proteins that influence the structure of chromatin. As 
described earlier, chromatin structure has an important role in the accessibility of DNA 
to proteins, and therefore in gene expression. Modifications of histones (acetylations, 
methylations, phosphorylations or ubiquitinations) by transcription factor-binding proteins 
modulate the accessibility of DNA and specific recognition sites for nuclear factors can 
be created.19,105,126,137,182,221 Chromatin remodellers form another class of protein complexes 
that transcription factors can bind to in order to influence chromatin structure. In an ATP-
dependent manner, they alter DNA-histone contacts within nucleosomes, thus influencing 
the accessibility of the DNA sequence.14 On the basis of the similarities of their ATPase 
subunits, these complexes can be divided into three classes: the Swi2/Snf2, Isw1, and Mi-2 
chromatin remodelling machines.
In addition to the DNA binding and activation/repression domains, most transcription fac-
tors have sites that are involved in post-translational modifications. These modifications in-
clude phosphorylation,99 acetylation,11 sumoylation,79 glycosylation109 and ubiquitination.226 
Numerous aspects of transcription factors have been shown or postulated to be the result of 
modifications, such as protein-protein interaction, protein stability, subcellular localisation 
and DNA binding.
In a cellular differentiation process, such as erythropoiesis, quantitative and temporal con-
trol of gene expression is a prerequisite. This is established by the presence of the appropri-
ate transcription factors, the fine tuning by posttranslational modifications and cooperation 
of multiple housekeeping- and tissue-specific transcription factors functioning in different 
complexes.134,195 One of the many transcription factors that are of vital importance for nor-
mal erythropoiesis is the erythroid Krüppel-like factor.
EKLF
History
The erythroid Krüppel-like transcription factor EKLF was initially discovered in a fishing 
expedition for novel erythroid genes. It was isolated by enriching genes that are expressed 
in a mouse erythroleukemia cell line but not in a mouse monocyte-macrophage cell line.147 
The cDNA encodes a protein of approximately 38kD. Initially its expression was found 
in bone marrow and spleen, the two hematopoietic organs of the mouse. Further studies 
showed that the expression of EKLF is restricted to erythroid cells.156,169,197
Sp/XKLF family
Most transcription factors are grouped into families on the basis of common DNA- or 
protein-binding domains. EKLF has been classified to the Sp/XKLF (specificity protein/
Krüppel-like factor) family of transcription factors.29,174,215 These transcription factors bind 
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and act through GC and GT/CACC boxes that are present in promoters, enhancers and locus 
control regions of numerous genes. An 81 amino acid DNA binding domain, found close 
to the C-terminus, defines the transcription factors of the Sp/XKLF family. It consists of a 
combination of three conserved Cys2His2-type zinc fingers.174 The name of this family of 
proteins derives from the observation that a similar arrangement of zinc fingers was found 
in the Drosophila segmentation gene Krüppel.193 In the human genome, 24 genes have been 
classified as belonging to this family of transcription factors. Eight of them belong to the 
sub-family of Sp-factors (Sp1-Sp8). In addition to the zinc-fingers, Sp-factors contain a 
conserved motif immediately N-terminal to the zinc finger domain.29 The Krüppel-like fac-
tors are more heterogeneous, but form a subgroup on the basis of additional conserved resi-
dues between each finger.23 The ‘X’ usually indicates the major expression site of the factor, 
i.e. erythroid cells (EKLF), gut (GKLF),194,232 intestine (IKLF),48 lung (LKLF),5 ubiquitous 
(UKLF)141 or fetal (FKLF).8 Another ubiquitously expressed factor has been named basic 
(BKLF) because its N-terminus is rich in basic residues.52 Although these abbreviations are 
commonly used for the proteins, the human gene nomenclature committee has assigned 
different official names to the factors. For EKLF, LKLF, BKLF, GKLF and IKLF these are 
respectively KLF1 to KLF5, UKLF is named KLF7 and the official name at this moment 
for FKLF is TIEG2.
EKLF in erythropoiesis
Expression of EKLF is largely restricted to the erythroid cell lineage and is expressed both 
in primitive and in adult erythropoietic cells.197 The promoter of the EKLF gene contains a 
functional binding site for the transcription factor GATA-1, suggesting that the expression 
of EKLF is dependent on and downstream of GATA-1.51 GATA-1 is expressed and func-
tional in primitive and adult erythroid cells.67,78,211
EKLF binds DNA at CACC-boxes, which are found in many erythroid gene promoters.181 
EKLF specifically binds the sequence 5’-CCA CAC CCT-3’.147 β-thalassemia patients that 
carry mutations in the EKLF binding site in the β-globin promoter illustrate the importance 
of this high affinity site. The loss off affinity for binding of EKLF reduces the expression of 
β-globin strongly.70,73,128,160,209 Furthermore, EKLF has a higher affinity for the human β-globin 
promoter than the γ-globin promoter, which has a similar but not identical CACC box.61
To determine the role of EKLF in vivo, the gene has been knocked out in mice.156,169 Mice 
heterozygous for the EKLF gene appear completely healthy. In the absence of EKLF 
however, mice die around E14. The primitive blood cells function sufficiently for normal 
survival of the EKLF knockout mice during embryonic development up to approximately 
E12. The expression of embryonic globins εy and βH1 is not influenced by the absence 
EKLF. So far, no abnormalities have been described for EKLF-/- primitive cells. However, 
the gene is expressed in wild type primitive cells and the low expression of the βmaj gene 
in these cells is dependent on EKLF.210 Furthermore, an EKLF-dependent reporter gene has 
been used to demonstrate that EKLF is a transcriptional activator in embryonic erythropoi-
esis.205 In Chapter 3, we describe the first endogenous target genes for EKLF in primitive 
cells. These are the Alpha Hemoglobin Stabilising Protein (AHSP) and Erythroid Protein 
Band 4.9 (Epb4.9). AHSP is an abundant erythroid-specific protein that protects cells from 
precipitation of free α-globin by forming a stable complex with it.120 Epb4.9 is an actin-
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binding and bundling protein of the erythrocyte membrane skeleton and it is required for the 
maintenance of the erythrocyte shape and membrane mechanical properties.119
When hematopoiesis has switched to the fetal liver, EKLF knockout mice develop a fatal 
anemia that is caused by strongly reduced β-globin expression. In contrast, α-globin gene 
expression does not appear to be dependent on EKLF. Furthermore, fetal liver-derived 
erythroid cells of EKLF-/- mice have an abnormal morphology. In particular, most of the 
cells retain a nucleus. Interestingly, definitive erythroid cells of mice with deleted βmin 
and βmaj genes have morphological abnormalities that are more like those found in human 
β-thalassemia than those found in EKLF-/- fetuses.231 This was the first indication that the 
β-globin genes are not the only target genes of EKLF. Stronger evidence that non-globin 
EKLF target genes contribute to the definitive red blood cell abnormalities and prenatal 
death in EKLF-/- fetuses came from a transgenic rescue study. EKLF-/- mice could not be 
rescued by expression of exogenous human γ-globin. Despite efficient production of hybrid 
hemoglobin, consisting of mouse α- and human γ-globin in the fetal livers, hemolysis was 
not corrected and survival was not prolonged.168 This strongly suggests that EKLF regulates 
more essential genes in erythropoiesis. In Chapter 3, we describe a number of such non-
globin EKLF target genes.
Domains in EKLF
The gene coding for EKLF in the mouse is located at chromosome 8.110 Three exons code 
for a 357 amino acid protein of approximately 38 kD.147 The cDNA contains two potential 
translation start sites. The second ATG site, corresponding to Met
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 in the open reading 
frame appears to be exclusively used as the start codon. In the literature, the amino acids are 
commonly numbered from the first ATG site as in Figure 4.
The genomic structure is highly conserved between mice and human.22,218 The DNA bind-
ing domain, consisting of three Cys2His2 zinc fingers, is the most conserved part. The 
homology of this domain between both genes is about 90%. Consequently, the proteins are 
believed to recognize the same DNA sequences with very similar affinity. In mice, the zinc 
fingers span the region from aa293 to aa376. 
Since EKLF is a nuclear protein, it has to be imported from the cytosol to the nucleus. The 
C-terminal domain, more precisely aa275-aa376, contains two separable Nuclear Localisa-
tion Signals (NLS).167,180 The first NLS is a basic domain adjacent to the zinc fingers, aa275-
aa296, and is called NLS1. The zinc finger domain itself (aa293-aa376) is called NLS2 and 
is more efficient than NLS1. However, the most efficient nuclear localisation is found with 
the entire domain. Importins, that are involved in the import of proteins from the cytosol to 
the nucleus,136 can bind this domain. Basic amino acids are essential for this binding; after 
mutation of the basic amino acids in the NLS of EKLF to alanine, the protein accumulated 
in the cytosol. Loss of the tertiary zinc finger structure could not account for the altered 
localisation; EKLF with histidine to alanine point mutations in the first zinc-chelating 
histidine of all three fingers was exclusively found in the nucleus.167 These mutations are 
known to destabilise the zinc finger tertiary structure.46 Interestingly, the basic residues of 
all mammalian Krüppel zinc fingers are highly conserved, indicating that they form a com-
mon NLS shared by all Krüppel family members.167 The N-terminal basic region is only 
shared by EKLF, LKLF and GKLF.23
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The proline-rich amino-terminal domain, aa19-aa292, is called the transactivation domain 
and can be separated from the DNA binding domain.24 Two sub-domains are reported to 
enhance transactivation.41,166 The first transactivation domain is located in the first 40 amino 
acids of the protein. The second consists of 85 amino acids at position aa158-aa243. Both 
transactivation domains, bound to the DNA binding domain, activate a reporter gene to wild 
type levels. This indicates that these domains are functionally redundant.166 In this respect, 
EKLF is similar to another Sp/XKLF family member, Sp1, which also contains two potent 
transactivation domains that are functionally redundant.49 
The transactivation domain contains serine and threonine residues that are phosphorylated 
in vivo.163 The phosphorylation status of EKLF is thought to play an important role in the 
control of activity of the transcription factor. Threonine41 lies within a consensus that is 
recognized by casein kinase II (CKII) (see Figure 4). CKII is ubiquitously expressed and 
modifies the activity of a range of substrates by phosphorylation, including transcription 
factors. In the human EKLF protein, a CKII target sequence is found at the same position,218 
suggesting an important function for this site. Mutations in the consensus site indicate that 
threonine41 is indeed phosphorylated by CKII, and that phosphorylation of this site is 
essential for EKLF’s transactivation activity. Although serine residues in EKLF are also 
phosphorylated, the significance of these modifications has not yet been investigated. 
E-RC1
DNA is packaged in chromatin (see ‘Chromatin and transcription’), which has a repressive 
effect on transcription. A number of complexes have been described that counteract this 
repressive effect. One of these complexes is the SWI/SNF complex.138 It is an ATP-de-
pendent chromatin-remodelling complex that changes the chromatin structure by altering 
DNA-histone contacts within nucleosomes. It has been shown that EKLF requires a SWI/
SNF-related chromatin-remodelling complex for transactivation of the β-globin gene when 
the DNA template is packaged in chromatin. The EKLF-SWI/SNF complex generates a 
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Figure 4. Structure of mouse EKLF
The amino acids of the EKLF protein are numbered 19 to 376. The DNA binding domain (aa293-aa376) con-
sists of three zinc fingers (ZF1 to ZF3). The C-terminal domain also contains Nuclear Localisation Signals 
(aa275-aa376). aa19-aa292 is proline rich and contains two transactivation domain (TD). CKII recognizes 
the consensus TQED and phosphorylates T41. Both K288 and K302 are acetylated by CBP. The posttran-
scriptional modifications of T41 and K288 play an important role in the transactivation potential of EKLF.
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DNAseI hypersensitive, transcriptionally active β-globin promoter in vitro. The SWI/SNF-
related complex is called EKLF co-activator-remodelling complex 1 (E-RC1). Factors in 
this complex are homologues of yeasts BRG1, BAF170, BAF155, BAF47 and a subunit 
that is unique to higher eukaryotes, BAF57.7
EKLF is necessary for recruitment of two E-RC1 subunits, BRG1 and BAF170 near the 
transcription initiation site of the β-globin promoter, suggesting that the complex uses 
EKLF for specific targeting.132 Further studies showed that the two subunits BRG1 and 
BAF155 are necessary and sufficient for targeted remodelling and transcriptional activation 
by EKLF in vitro. The DNA binding domain of EKLF is sufficient for targeting the two 
subunits to the β-globin promoter. However, to activate transcription the EKLF activation 
domain is required.114
Acetylation
The acetylation of histones results in general in a more open chromatin structure. Hypo-
acetylated histones on the other hand are associated with transcriptionally inactive or silent 
chromatin.129 The acetylation pattern of histones is controlled by two families of proteins 
with opposing activities; histone acetyl-transferases (HATs) and histone de-acetylases 
(HDACs). Surprisingly, EKLF appears to interact with proteins of both families. Transcrip-
tional repression is often accomplished by binding with corepressors, such as mSin3a, and 
recruiting HDACs to the site of interest.131 EKLF interacts with both mSin3a and HDAC1, 
suggesting that EKLF can function as a transcriptional repressor.42 The two proteins bind 
EKLF at its DNA binding domain. It is important to note that the zinc finger domain, when 
bound to mSin3a and HDAC, has lost its capacity to bind DNA. Gene repression was only 
observed when the mSin3a-HDAC complex was targeted to a promoter by another DNA 
binding domain fused to EKLF or its zinc fingers. So far, there is no evidence that EKLF 
functions as a transcriptional repressor in vivo.
Since EKLF is better known as a transcriptional activator, it is less surprising that a number 
of studies reported interactions with acetyl-transferases. CREB-binding protein and p300 
are two widely expressed factors that are believed to regulate gene expression in most cell 
types with their histone acetylation activity.26 However, they can acetylate non-histone nu-
clear proteins as well. CBP and p300 have been shown to interact with EKLF. They bind 
its zinc finger domain, as well as its transactivation domain.234 As a result of the binding of 
CBP and p300, EKLF is acetylated. EKLF contains 11 lysines that are potential acetyla-
tion targets. However, only K288 in the transactivation domain and K302 in the first zinc 
finger of the DNA binding domain are acetylated by CBP (see Figure 4).235 Interestingly, 
these lysines are conserved; K302 is conserved across all KLF family members, whereas 
K288 is shared by EKLF, LKLF and GKLF. Thus, in addition to the phosphorylation events 
described earlier, acetylation is a second post-translational modification of the EKLF pro-
tein. Maximum activity of EKLF is dependent on its acetylation status. However, the DNA 
binding capacity of EKLF is not influenced by acetylation. Mutagenesis of K288 to alanine 
indicated that acetylation of this lysine in particular plays an important role in the transacti-
vation potential of EKLF. This is explained by a higher affinity for the SWI/SNF chromatin 
remodelling complex.235
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β-globin locus
The β-globin locus has been widely used as a model to study gene regulation. An important 
contribution to the understanding and interest in the β-globin locus is the high incidence 
of genetic mutations and deletions, leading to hemoglobinopathies described earlier. The 
strictly tissue-specific and developmentally regulated expression of the genes makes the 
β-globin locus an interesting model for the studies of gene regulation.
Both the human and mouse β-globin locus contain a number of genes, well-characterised 
promoters, enhancers and a locus control region. The genes encode for the β-globin-like 
proteins. Together with two α-globin-like proteins and four heme groups they form the 
tetrameric molecule hemoglobin, the oxygen binding protein in red blood cells.171 All the 
globin genes originate from one ancestral globin gene. About 450 million years ago, this 
ancestral globin gene duplicated, leading to the separate α- and β-globin genes.92 After 
duplication, these genes evolved independently of each other, ending up on separate chro-
mosomes in birds and mammals. Both the α- as well as the β-globin genes duplicated 
several times.80,94 For the mouse β-globin locus this led to four functional genes; εy, βH1, 
β-major (βmaj) and β-minor (βmin). The expression of the genes is strictly regulated dur-
ing development. The genes are arranged from 5’ to 3’ in the same order as their devel-
opmental expression (see Figure 5); Embryonic, yolk sac-derived erythroid cells express 
primarily εy- and βh1-globin. Expression of βmaj and βmin is at a very low level in these 
primitive erythroid cells. Their expression becomes high around E11 when erythropoiesis 
commences in the fetal liver.31,223,227 From this stage onwards, the embryonic genes are shut 
down. In the early adult erythroid cells, the βmaj to βmin ratio is about 60% to 40%. This 
changes to a ratio of 80% to 20% in later stages of development. These two genes appear to 
compete with each other for transcription, since only one of the genes is actively transcribed 
at any time point210 and deletion of the βmaj-promoter and gene results in a 50% increase in 
βmin-gene transcription.53,196
A necessity for the switch in globin expression may be the competition for oxygen between 
blood cells from the embryo/fetus and the maternal erythrocytes. Adult-type hemoglobin 
would not be able to take up oxygen from the maternal blood efficiently. The early expressed 
globin-like genes form a type of hemoglobin that has a higher affinity for oxygen than the 
adult type. Therefore, oxygen can efficiently be extracted from the maternal blood.179
A number of cis-regulatory elements are important for the erythroid-specific and devel-
opmentally controlled expression of the genes in the β-globin locus. All the genes contain 
promoters within 200 bp 5’ of the transcriptional start site. The functional promoters can be 
detected as DNAseI hypersensitive sites when they are active. In mammals, the globin pro-
moter sequences are highly conserved. All promoters contain three conserved, although not 
completely identical regions: CACC, CCAAT and TATA boxes. Complete deletion of the 
embryonic gene promoters results in elimination of embryonic gene expression.101 Single 
base mutations in these sequences leads to a significant decrease in level of transcription.153 
The significance of the promoters is further demonstrated by mutations that lead to tha-
lassemia or HPFH.157,160,230 In fact, some thalassemias are caused by mutations in the CACC 
box, that influence the binding capacity of EKLF.73,128 This indicates that binding of EKLF 
to the CACC box in necessary for normal adult globin expression.
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The promoters alone are not sufficient for a controlled expression of the globin genes. 
The first indications that other sequences apart from the genes are necessary for normal 
expression came from the study of some β-thalassemia patients. The Dutch deletion-type 
thalassemia patients have a deletion of about a 100 kb upstream of the β-globin gene. The β-
globin gene including its promoter is left intact but is not transcribed.122 Further study of the 
deleted sequence revealed 5 DNAseI hypersensitive sites.213 These HS together are called 
the Locus Control Region (LCR), which is necessary for normal globin gene expression. 
Transgenic mice with a DNA fragment in which the LCR is linked to the human β-globin 
gene show high level, tissue-specific and copy-number dependent expression.89
The LCR is an evolutionary conserved region. On the basis of sequence homology, the LCR 
in the mouse β-globin locus was found.93,111,149 The mouse LCR consists of 6 HS, spread 
over ~30 kb upstream of the εy-globin gene. The cores of these HS contain binding sites 
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Figure 5. Mouse β-globin locus and β-globin expression
a The mouse β-globin locus contains four globin like genes (triangles) whose expression is con-
trolled by the Locus Control Region (LCR) that consists of 6 Hypersensitive sites (HS) (ovals). 
Furthermore it contains 3 more distally located HS and a number of genes that are not expressed 
in erythroid cells (rectangles). b Embryonic, yolk sac derived cells express mainly εy and βh1. 
High expression of the definitive βmaj and βmin genes starts around E11 when erythropoiesis 
commences in the fetal liver. After birth, blood is mainly formed in the bone marrow.
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b
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for transcription factors and comprise the functional components of the LCR. Complete 
deletion of the LCR leads to a severe reduction in expression of all mouse β-like globin 
genes, showing that the LCR is necessary for high-level transcription.16 The functions of the 
individual HS of the mouse LCR are less extensively studied than those in the human LCR. 
However, the deletions of every mouse HS have been described. Individual deletion of the 
first four HS, 5’HS1 to 5’HS4, all have a comparable effect on the expression of the endog-
enous globin locus; the expression levels of the embryonic genes, εy- and βh1, are hardly 
reduced. However, all four deletions decrease the expression levels of the adult genes βmaj 
and βmin with approximately 25-30%.18,74,103 Deletion of 5’HS5 and 5’HS6 does not result 
in a decreased level of gene expression.17 Although the expression levels of the adult genes 
are reduced, none of the HS deletions perturbs the developmental gene expression pattern 
or affects the DNAseI hypersensitivity of other HS.18 Because of the homology between 
the human and mouse LCR, it is assumed that the function of comparable HS is maintained 
during evolution. Although the individual roles of the HS remain unclear, both in the human 
and mouse β-globin locus, 5’HS2 and 5’HS3 appear to be the most important sites for ef-
ficient transcription.35,64,74,76,103,172,173,175,201 The 5’HS2 of the human locus has been shown to 
function as a classical enhancer in both transfection and transgenic mouse studies.54,184,214
The core regions of the HS, several hundred base pairs, and a number of binding sites for 
erythroid-specific and ubiquitous transcription factors within this region are highly con-
served.13,93,158 Among these, potential EKLF binding sites are present and at least one poten-
tial binding site in human 5’HS3 is a functional EKLF binding site in vivo.81,205 In transgenic 
mice that carry a human β-globin locus, EKLF is necessary for the formation of DNAseI 
hypersensitivity at 5’HS3 and the β-globin promoter.228
Apart from the HS in the LCR, some HS are found more upstream of the LCR and down-
stream of the genes. The HS found downstream of the genes in mouse and human is called 
3’HS1.213 In the mouse, two HS are found at 60.7 and 62.5 kb upstream of the εy-promotor 
(5’HS-60/-62), homologous to a HS found 111 kb upstream of the human ε-globin gene 
promoter.68 So far, their function remains enigmatic. Deletion of 5’HS-60/-62 did not effect 
globin expression.68 Interestingly, the distal HS contain sequence motifs that appear to bind 
CTCF.34,69 CTCF (CCCTC-binding factor) is believed to play a central role in many chro-
matin insulators.15 Insulators can block the communication between gene promoters and 
enhancers, and can mark a boundary between open and condensed chromatin. Therefore, 
these distal HS may define a physical border of the β-globin locus.
Active Chromatin Hub
Since the discovery of the LCR, a number of models have been proposed for the regulation 
of developmental control and high level of gene expression over such a long distance. The 
three basic models are the accessibility model, the scanning model and the looping model. 
The accessibility model proposes that the function of the LCR is merely to establish an open 
chromatin structure.32,140 This would enable stage-specific factors to bind the more proximal 
regulatory elements of the genes. After opening of the chromatin, the genes would be acti-
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vated in a stochastic manner, depending on the trans-acting factor environment. In the scan-
ning (or tracking) model, the LCR binds the transcriptional machinery, which then scans the 
DNA in a unidirectional way in order to find the gene promoters.98,212 The looping model 
proposes a direct interaction between the LCR and promoter, with the intervening DNA 
sequence looping out of the LCR-promoter complex.178 The looping model best explains a 
number of properties of the (human) β-globin locus. Dillon and colleagues described the 
transcriptional effects of an additional marked β-globin gene in the human β-globin locus 
in transgenic mice.58 The marked β-globin gene was inserted at varying positions. Compar-
ing the expression levels of the β-globin gene and the marked β-globin gene showed that 
the most proximal gene to the LCR has the highest expression. Furthermore, the relative 
expression of the most proximal gene decreased when positioned more closely to the more 
distal gene. The accessibility model would predict an equal transcription of the two genes, 
irrespective of their position. The scanning model cannot explain differences in expression 
at varying distances between the genes. After insertion of the marked β-globin gene, the 
combined expression of the two genes equals that of the expression of the β-globin gene in 
the wild type locus. This suggests that the two genes compete for expression, which is best 
explained by the looping model. Two other papers further demonstrate that multiple genes 
in the globin locus are transcribed alternately rather than simultaneously.88,229 These find-
ings have resulted in the proposal of a flip-flop mechanism, in which the genes alternately 
form a complex with the LCR to be actively transcribed. 
In 2002 two techniques were developed with which it was finally demonstrated that the 
LCR is in close proximity to the actively transcribed gene.39,208 One approach is called 
RNA TRAP (tagging and recovery of associated proteins).39 Primary transcripts are hy-
bridised with a horseradish peroxidase (HRP) labelled probe. Biotin-tyramide is added, 
which, under the control of the localized peroxidase becomes a highly reactive radical 
intermediate that covalently attaches to chromatin proteins in the immediate vicinity. 
This deposition on chromatin can be quantified and is an indication for its vicinity to the 
transcribed gene. 
The second technique is called chromosome conformation capture (3C).56 Cells are 
crosslinked with formaldehyde, followed by restriction enzyme digestion of the DNA. 
After de-crosslinking, the samples are ligated under conditions that favour the ligation of 
DNA fragments that are physically connected through the crosslinks. Quantitative PCR 
across the junctions is used to determine the relative crosslinking frequencies between 
restriction fragments in the locus. This is an indication of the nuclear proximity of DNA 
fragments in vivo. The advantage of the first technique is that it uses primary transcripts. 
Therefore, the results are obtained only from cells that are actively transcribing the gene 
of interest. An advantage of the 3C technique is that interactions between DNA fragments 
over an entire locus can be analysed, regardless whether it is transcriptionally active or not. 
With this technique it was shown that the actively transcribed gene is not only in close prox-
imity to 5’HS2, but to all of the HS in the LCR and to the three distal HS; 5’HS-62/-60 and 
3’HS1.208 This complex is called the Active Chromatin Hub (ACH) (Figure 6). In erythroid 
precursors that do not express globin yet, a substructure of the ACH is found. This consist 
of (at least) the distal HS and the HS at the 5’ site of the LCR. For active transcription, the 
gene that will be transcribed and the HS at the 3’ site of the LCR participate to form the 
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complete ACH. In embryonic cells the actively transcribed gene is either εy or βH1, in adult 
cells βmaj or βmin.165
An important function for the ACH may be the spatial clustering of binding sites for 
trans-acting factors. As a result, the local concentration of these factors will increase, 
which is necessary for efficient transcription.38,43,55,62,108 Thus, the ACH is proposed to 
represent a nuclear compartment dedicated to RNA polymerase II transcription of β-
globin genes.
It is not known how the separated cis-regulatory elements establish an ACH. Three models 
have been proposed, random collision, tracking25 and linking.33 The random collision model 
proposes that the flexibility of the chromatin permits transcription factors, bound to regula-
tory sequences, to randomly contact each other. Complex formation depends on the affinity 
between the proteins.55 The tracking and linking models are basically combinations of the 
earlier proposed models for enhancer function, with the addition of the end result: i.e. that 
the LCR is in close proximity to the actively transcribed gene. Both models assume a linear 
propagation of a signal along intervening DNA from the LCR to the promoter. The tracking 
model proposes that this signal is an enhancer-bound protein complex, the linking model 
proposes a growing chain of proteins. Distinguishing between these models is quite diffi-
cult. So far, very little is known about the dynamics of ACH formation, or the proteins in-
volved. In Chapter 4 we show that EKLF is indispensable for the completion of the ACH. In 
the absence of EKLF, an ACH substructure similar to that observed in erythroid precursor 
cells was found. Apparently this substructure is formed independent of EKLF. However, 
the completion of the ACH, which entails the participation of the actively transcribed gene 
and the HS at the 3’ site of the LCR, requires the presence of EKLF.
3’
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Figure 6. Active Chromatin Hub
In erythroid cells, the β-globin locus is spatially organised into an ACH 
that consists of the hypersensitive sites and the actively transcribed gene.
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Scope of the thesis
This thesis describes experiments that shed light on the role that the transcription factor 
EKLF plays in erythroid gene regulation.
Chapter 2 describes an in vitro culture method with which molecular aspects of erythro-
poiesis can be studied. Primary mouse erythroid cells are kept proliferating as progenitors. 
The cells undergo synchronous terminal differentiation after induction with physiological 
agents. 
Chapter 3 describes genes whose expression is controlled by EKLF. Using the in vitro 
culture method, described in Chapter 2, and micro array experiments, we found a number of 
genes that are not upregulated during terminal differentiation of adult erythroid cells in the 
absence of EKLF. Apart from the target genes in adult erythrocytes, we found target genes, 
AHSP and Epb4.9, whose expression is EKLF dependent in primitive cells as well. The 
absence of AHSP and Epb4.9 in primitive cells in EKLF null fetuses causes precipitation of 
globin chains and an instable cell membrane.
The βmaj gene is a known EKLF target. Its transcription requires a spatial conformation 
of the globin locus called the Active Chromatin Hub. This consists of the cis-regulatory 
HS sites and the actively transcribed gene. In Chapter 4 we describe that in the absence of 
EKLF a substructure of the ACH is formed, similar to the substructure found in erythroid 
progenitor cells that do not yet express globin. Thus, we propose a model in which EKLF is 
necessary for the completion of the substructure into a complete and fully functional ACH.
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Introduction
To study molecular processes in erythropoiesis, it is desirable to have a culture system in 
which cells undergo a synchronous, in vivo-like differentiation program. Terminal differ-
entiation includes a limited number of cell divisions, cell size reduction, accumulation of 
hemoglobin and eventually enucleation of the cells.1 Most established erythropoietic cell 
lines have a leukemic origin. Therefore, it is unlikely that their differentiation program is 
equivalent to that of differentiating cells in vivo. This is in fact indicated by a relative low 
accumulation of hemoglobin. In Friend-virus induced murine erythroleukemia (MEL) cells, 
hemoglobin constitutes only 10% of total protein after 96 hours of differentiation,8 whereas 
protein extracts from erythrocytes of peripheral blood contain about 95% hemoglobin.7 Fur-
thermore, MEL cell differentiation is induced by non-physiological reagents such as dime-
thyl sulfoxide (DMSO). Another cell line, the v-myc/v-raf transformed J2E cell line, does 
initiate differentiation upon induction by the physiological agent erythropoietin (EPO). 
However, these cells do not perform an in vivo-like differentiation program with respect to 
a limited number of terminal cell divisions; the cultures continue to proliferate at the time 
of highest globin expression.9
Another culture system was developed in which erythropoietic progenitors proliferate and 
can undergo a synchronous terminal differentiation program. Originally this culture method 
was applied to avian erythropoietic progenitors22 and later to mouse erythropoietic progeni-
tors.5,20 In this culture system, pro-erythroblasts are kept proliferating under the control of 
EPO, Stem Cell Factor (SCF) and the glucocorticoid hormone dexamethasone (Dex). EPO 
is necessary during proliferation of pro-erythroblasts, as well as during the terminal differ-
entiation of the cells. It prevents the cells from undergoing apoptosis. Erythropoietic cells 
become EPO-dependent after the CFU-E-stage of differentiation; mice lacking the EPO-
receptor die around day 12.5 of gestation from failure of definitive erythropoiesis.25 The 
fetuses produce normal BFU-E and CFU-E progenitors, but fail to produce hemoglobinised 
erythrocytes.10 The combination of SCF and Dex supports cell proliferation. The receptor 
for SCF, c-Kit, is expressed on the first erythropoietic progenitors, up to the stage of the 
basophilic erythroblast.19 In the absence of SCF or c-Kit, mice suffer from severe anemia.24 
SCF increases the number of cell divisions before progenitors mature in erythrocytes.14 
Dex regulates gene expression via the glucocorticoid receptor (GR). The GR is not eryth-
roid-specific and mice lacking the GR die at birth with impaired development of several 
organs.4 Glucocorticoids (GCs) are expressed mainly as a result of stress to maintain home-
ostasis.2 Situations in which stress erythropoiesis is induced are blood loss, hemolysis and 
conditions of oxygen deprivation. As a result of the released GCs the number of erythroid 
progenitors is expanded through additional cell divisions.3 Therefore, the proliferation of 
pro-erythroblasts in vitro under the control of EPO, SCF and Dex, is thought to be related 
to stress erythropoiesis. Terminal differentiation is induced by removal of Dex and SCF and 
a tenfold increase of the EPO concentration. Under these conditions, cells undergo four to 
five rapid cell divisions, accumulate hemoglobin, the nucleus condenses and eventually the 
cells enucleate.5,20 The pro-erythroblasts are typically isolated from day 12.5 mouse fetal 
livers. Hence, this is a culture system in which primary pro-erythroblasts undergo a reliable 
in vivo-like differentiation following expansion and synchronisation.
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Using this culture system, primary erythroblasts can be kept proliferating for 15-20 days. 
This results in an expansion of more than 10,000-fold. When cells are kept longer in the 
proliferation medium, they undergo abortive differentiation and/or cell death. To over-
come this problem, an immortalised pro-erythroblast cell line was established from fetal 
liver cells of p53-/- mice. p53 is a tumor suppressor gene; in absence of p53 hematopoietic 
cells are immortalised rapidly and spontaneously.12 After long term proliferation and 
cloning an immortalised pro-erythroblast cell line was established, termed the I/11 cell 
line. Like the short term proliferating cells, these immortalised cells are characterized as 
pro-erythroblasts by their high expression of c-Kit and transferrin receptor, low levels 
of Ter-119 and lack of expression of markers for myeloid, lymphoid, or multipotent 
progenitors.20 Proliferation of I/11 cells, like primary pro-erythroblasts, dependents on 
EPO, SCF and Dex. Furthermore, upon induction the cells undergo the characteristics of 
terminal differentiation such as size reduction, massive hemoglobinisation and enuclea-
tion.20 The gene expression profiles of the primary erythroblasts and the I/11 cells have 
been studied revealing very similar expression patterns during differentiation. Genes with 
known functions follow the expected expression pattern.5 Examples are; the up regula-
tion of Bcl-X
L
, an anti-apoptotic member of the Bcl-2 gene family;6 down regulation of 
the receptor for SCF, c-Kit19 and the glucocorticoid receptor.23 The transcription factors 
GATA-126 and EKLF are both up regulated during the initial stages of differentiation and 
down regulated at late stages of differentiation.
We have used this culture system to study the erythroid-specific transcription factor EKLF 
in erythropoiesis. EKLF-/- mice die around day 14 of fatal anemia, because of a deficit of β-
globin expression.15,17 However, the phenotype cannot be rescued by exogenous expression 
of human γ-globin, despite production of sufficient amounts of hemoglobin,16 indicating 
that EKLF regulates other essential genes during definitive erythropoiesis. Although EKLF 
is necessary for normal definitive erythropoiesis, fetuses lacking the transcription factor 
develop a fetal liver with normal numbers of CFU-E progenitors. This recently established 
culture system provides an opportunity to expand EKLF-/- erythroid progenitors and study 
terminal differentiation in the absence of EKLF. In the current chapter we describe our 
efforts at generating an EKLF-/- immortalised cell line while in Chapter 3 we describe the 
phenotype of EKLF-/- definitive erythroblasts and the discovery of a number of novel EKLF 
target genes.
Results and Discussion
Concordant to the establishment of the I/11 culture, we attempted to make an immortal-
ised EKLF-/- cell line by using p53-deficient cells. We therefore crossed heterozygous 
EKLF+/- mice with heterozygous p53+/- mice. The EKLF+/- mice carried a copy of the 
human -globin locus.18 Subsequently, EKLF+/- p53+/- mice were crossed and fetal livers 
were isolated at day 12.5 of gestation from a number of litters. The litter that we focus 
on in this chapter consisted of 7 embryos, including 1 EKLF+/+ and 1 EKLF-/-. These two 
embryos were also deficient for p53. The fetal livers were resuspended in proliferation 
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medium. During the first 12 days of proliferation, the p53 genotype did not appear to 
have an effect on the cell cultures. In all cultures the cells were kept at a density of about 
2 million cells per ml, and the number of cells doubled every 24 hours. The EKLF-/- cells 
grew slightly better than wild type and heterozygous cells; the culture expanded slightly 
faster and fewer smaller, differentiating, cells were formed compared to the controls. 
During proliferation of the pro-erythroblasts, a small number of cells escape the self-re-
newing program and undergo ‘spontaneous’ terminal differentiation. This is indicated by 
the appearance of small cells in the culture. In the absence of EKLF and its target genes 
the cells are apparently less prone to start their terminal differentiation programme, re-
sulting in slight proliferative advantage. There are no signs of increased apoptosis as has 
been observed in pro-erythroblasts of some other key regulators of erythropoiesis such as 
GATA-121 and the erythropoietin receptor.10 
After 10 days of proliferation, parts of the cultures were induced to terminally differentiate. 
Wild type and EKLF+/- cells displayed in vivo-like differentiation, based on the observation 
that they underwent 4 to 5 rapid cell divisions accompanied by cell size reduction, accumu-
lated hemoglobin and eventually enucleated. EKLF-/- cells underwent rapid cell divisions as 
well, but their cell size did not decrease as much as that of wild type and heterozygous cells. 
Furthermore, in the absence of EKLF there was hardly any accumulation of hemoglobin 
(data not shown; similar to data in Chapter 3). 
In several experiments, cultures of cells containing functional p53 became stationary after 
about two weeks of proliferation, showing increased terminal differentiation and cell death, 
in agreement with results from von Lindern et al.20 (data not shown). We therefore only 
continued with cultures of p53 null cells (cultures 1, 2 and 5, EKLF+/+, EKLF-/- and EKLF+/- 
respectively). Mature cells were removed by centrifugation through Ficoll at regular inter-
vals. After 5 weeks of proliferation, the cultures were again tested for their differentiation 
capabilities. Cell size distribution and hemoglobin content were measured at regular time 
points during differentiation. The differentiation results of these cells after 5 weeks of pro-
liferation were comparable to the results after 10 days of proliferation. Both EKLF+/+ and 
EKLF+/- cells accumulated hemoglobin, whereas the EKLF-/- cells failed to do so (see Figure 
1). The cell size distribution during the first 24 hours is similar for all three genotypes. After 
Figure 1. Hemoglobin accumulation
Hemoglobin accumulation of pro-eryth-
roblasts after 5 weeks of proliferation 
upon induction is comparable to the 
one found in primary erythroblasts (see 
Chapter 3). Hardly any hemoglobin is 
formed in EKLF-/- cultures compared to 
EKLF+/- and EKLF+/+ cultures. The val-
ues in the graph represent the amount of 
hemoglobin per cell volume in arbitrary 
units (see materials and methods).
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24 hours, the cell size in EKLF+/+ and EKLF+/- decreases and subsequently small, enucleated 
cells are observed by the appearance of a second peak. In the EKLF-/- cultures, the mean cell 
size decreases less and no enucleation is observed (see Figure 2).
Next, we wished to establish stable, clonal cultures for all three genotypes. After six weeks 
of continuous growth, EKLF+/+, EKLF+/- and EKLF-/- cells from the mass cultures were 
seeded in serum-free semi-solid medium (StemPro-Methocult). After 10 days, 60 colonies 
of each genotype were isolated and expanded in proliferation medium. Half of these colo-
nies, the ones that proliferated best, were partially induced for differentiation. After 2.5 
days, hemoglobin content was measured. On the basis of proliferation rates and hemoglobin 
accumulation after induction, we continued with cultures of 7 EKLF+/+, 6 EKLF+/- and 8 
EKLF-/- colonies. In an additional differentiation experiment, the EKLF+/- cultures and 3 
of the EKLF+/+ cultures did not accumulate significant amounts of hemoglobin and these 
cultures were discarded.
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Figure 2. Cell size distribution
Pro-erythroblasts that have been cultured for 5 weeks show a similar cell size distribution 
upon induction as primary pro-erythroblasts (compare with Figure 1a in Chapter 3). The ar-
row indicates the cell size of enucleated cells. All cultures have a similar cell size distribution 
regardless of their genotype. Upon induction, the size of wild type and heterozygous cells 
decreases and after 48 hours enucleated cells appear. This is not found in absence of EKLF.
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To test whether the EKLF-/- phenotype in the cloned cultures could be rescued, we wanted 
to rescue the cells with exogenous expression of EKLF. Therefore a construct was cloned 
in the retroviral expression vector pBABE-puro.13 The construct codes for EKLF fused in 
frame with the hemagglutinin (HA) epitope tag. Two EKLF+/+ and 4 EKLF-/- cultures were 
transfected with HA-EKLF-pBABE-puro or empty pBABE-puro virus. Unfortunately, all 
the cultures failed to undergo a complete differentiation program. The EKLF-/- cultures 
transfected with the HA-EKLF transgene did not accumulate more hemoglobin during dif-
ferentiation than cultures transfected with empty vector. Moreover, in the same differentia-
tion assay, a non-transfected EKLF+/+ culture accumulated the same amount of hemoglobin 
as a non-transfected EKLF-/- culture. Based on these negative results, we decided to focus 
on the short-term cultures, as we obtained very promising results with such cultures (see 
Chapter 3). However, because we are now more experienced in culturing pro-erythroblasts, 
it might be worthwhile to perform a new series of experiments aimed at the derivation of 
immortalised EKLF-/- erythroid cell lines. The I/11 cell line is an immortalised cell line 
derived from a p53-/- fetal liver, that can still undergo a faithful differentiation program.5,20 
During the selection of this cell line, a considerable number of cells were found to be aneu-
ploid. In the attempts to derive immortalised EKLF-/- cell lines described here, we did not 
check the karyotypes of the cells. Therefore, aneuploidy may have contributed to the disap-
pointing differentiation results of the cloned cells.
Apart from the I/11 cells, another indication that p53-/- pro-erythroblasts are relatively 
easy to immortalise is the establishment of the R1 and R10 cultures. These cultures were 
started in the same period as the cultures described in this chapter. None of the embryos 
were both EKLF- and p53-deficient. The R1 and R10 cultures are derived from EKLF+/+ 
p53-/- embryos. Furthermore they carry the human β-globin locus. These cultures have 
been cloned successfully and have been proliferating for more than a year. All the cloned 
cultures still perform a reliable terminal differentiation upon induction. In our laboratory, 
these cultures are now frequently used as an alternative to the I/11 cells, having the benefit 
of the presence of the human β-globin locus. This indicates that p53-/- pro-erythroblasts are 
relatively easy to obtain, providing the means to generate erythroid cell cultures with differ-
ent genetic make-ups with an unlimited life span, yet retaining primary erythroid progenitor 
behaviour with respect to differentiation characteristics. The availability of mice carrying a 
transgene coding for a tamoxifen-inducible EKLF and the human β-globin locus provides 
a particularly attractive system for the generation of immortalised erythroid cell lines, since 
such mice could be crossed with the EKLF knockout. Tamoxifen inducibility of the EKLF 
could then be used to full advantage to study the kinetics and sequence of events leading 
to β-globin gene activation by EKLF (see Chapter 4), and activation of other EKLF target 
genes (see Chapter 3). Such a cell line would be amenable to use the complete array of tools 
available in modern biomedical sciences, such as chromatin immunoprecipitation assays, 
DNA micro arrays, and RNA interference experiments. However, the important issue of γ- 
to β-globin switching would still have to be addressed in mice, since cultured cells almost 
invariably switch to the expression of adult-type globins after a few days in culture.
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Materials and methods
Cultivation of murine erythroid progenitors
Fetal livers of day 12.5 mouse fetuses were disrupted and seeded into Stem-Pro-34TM 
medium supplemented with human recombinant erythropoietin (Erypo, Cilag AG, Swit-
zerland, 1 U/ml), murine recombinant stem cell factor (SCF, R&D Systems, Minneapolis, 
MN, USA, 100 ng/ml) and dexamethasone (Dex, Sigma, 10-6 M). Cell density was kept 
at approximately at 2x106 cells/ml by adding fresh medium. Typically the cultures were 
diluted twofold daily. Cell numbers and size distributions were determined daily, using an 
electronic cell counter (CASY-1, Schärfe-System, Reutlingen, Germany). Pro-erythrob-
lasts were enriched through Ficoll (lymphocyte separation medium, 1078 g/cm3, Eurobio, 
France) by centrifugation, when the cultures contained >40% dead and/or differentiated 
cells as estimated by size distribution.
Cloning of immortalised cell lines
After six weeks in culture, p53-/- erythroblasts were seeded into semisolid medium (Metho-
cel-containing StemPro-34 SFM, Life Technologies, Gibco BRL) containing SCF, EPO 
and Dex as above. After 7-10 days of incubation, large colonies were obtained. Of each 
genotype (EKLF+/+, EKLF+/- and EKLF-/-) 60 clones were picked from dishes with well-
separated colonies, and cultivated in 96-well plates. After ~4-6 days, colonies were inspect-
ed visually. Clones containing either a high proportion of mature cells, cells of irregular 
size/shape or exhibiting a slow proliferation rate were discarded. The remaining clones (15, 
20 and 34 respectively) were expanded and partially set up to differentiate. On the basis 
of hemoglobin accumulation in the differentiation experiment and proliferation kinetics, 8 
clones of each genotype were kept in culture. 
Terminal differentiation
Pro-erythroblasts were washed twice in PBS and seeded at 1.5x106 cells/ml in differentia-
tion medium (Stem-Pro-34TM medium supplemented with EPO (10 U/ml) and iron-saturated 
human transferrin (Sigma, 1 mg/ml). Cells were maintained at densities of 2-4x106 cells/ml, 
requiring daily dilution with fresh medium, between 24 and 50 h requiring dilution twice 
a day. Cell number and size distribution were determined using an electronic cell counter 
(model CASY1; Schärfe Systems). Hemoglobin content was quantified in a photometric 
assay as described.11 In short, 2–4 x 104 cells were washed in PBS, lysed in 20 µl H
2
O, and 
frozen until further analysis. 100 µl of reagent mix (0.5 mg/ml o-phenylenediamine (Sigma-
Aldrich) and 0.03% H
2
O
2
 in 0.1 M citrate/phosphate buffer, pH 5.0) was added to thawed 
samples. The reaction was stopped after ~2 min. with 20 µl 8 N H
2
SO
4.
 The 492 nm extinc-
tion of the reaction product was measured with an ELISA spectrophotometer. Extinction/
(cell number x average cell volume) was taken as a measure for hemoglobin content. 
Transfection of EKLF construct
A construct coding for a fusion protein of EKLF with an HA-tag was cloned in the retro-
viral expression vector pBABE-puro. The construct was transiently expressed in Phoenix 
cells. 40 h after transfection, cells were treated with 10 µg/ml mitomycinC (Kyowa Hakko 
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Kogyo) for 1 h and washed with PBS, followed by two additional washes after an interval 
of >4h. Two EKLF+/+ and four EKLF-/- cloned cell cultures (0.5 x 106/ml) were added and 
co-cultured for 24 h in proliferation medium. The cells were removed from the Phoenix 
cells and grown in 2 µg/ml puromycin-containing proliferation medium. The capacity to 
terminally differentiate was determined as described above.
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Abstract
Development of red blood cells requires multiple cellular processes including changes 
in cell morphology, globin expression and heme synthesis. Gene ablation studies have 
revealed transcription factors critical in this process, such as erythroid Krüppel like 
factor (EKLF or Klf1). Mice lacking EKLF die around embryonic day 14 because of 
defective definitive erythropoiesis, partly caused by a deficit in β-globin expression. 
To identify additional genes contributing to the severity of the EKLF knockout, we 
analysed the phenotype and gene expression profiles of wild-type and EKLF null pri-
mary erythroid progenitors that were differentiated synchronously in vitro. We show 
that EKLF is dispensable for the expansion of erythroid progenitors, but required for 
the last steps of erythroid differentiation. We identify novel EKLF-dependent genes 
involved in hemoglobin metabolism and membrane stability, providing an explana-
tion for the severity of the EKLF null phenotype. Strikingly, expression of these genes 
is also EKLF-dependent in primitive, yolk sac derived blood cells. Consistent with 
lack of upregulation of these genes we find previously undetected morphological ab-
normalities in EKLF null primitive cells.
Introduction
The anemias, caused by failure of erythropoiesis, constitute the most common human 
genetic disorders. Most of these disorders are caused by mutations or deletions in the cod-
ing sequences or regulatory elements of the α- or β-globin genes.41 A number of these 
mutations have marked the importance of specific promoter elements, such as the β-globin 
CACC box. Mutations within this box result in severe down regulation of β-globin gene 
expression.8,9,20 The CACC box motif is found in many erythroid gene promoters;33 it is a 
binding site for the transcription factor erythroid Krüppel-like factor (EKLF or KLF1), a 
member of the SP/XKLF transcription factor family.9,25 An 81 amino acid DNA binding do-
main, found close to the C-termini of all members, defines this family. The binding domain 
consists of a combination of three conserved Cys2His2-type zinc fingers.31 The expression 
of EKLF is largely restricted to the erythroid lineage,25,36 although expression in macro-
phages has been reported recently.23 Mice lacking EKLF die in utero around embryonic day 
14 (E14) from severe anemia associated with a marked deficit in β-globin expression.28,30 
The time of death coincides with the stage of development in which the fetuses become 
dependent on definitive, fetal liver-derived, erythroid cells, that take over the oxygen trans-
port from the primitive, yolk sac-derived cells. So far, no abnormalities in EKLF-/- primitive 
cells have been described. However, EKLF is expressed in these cells.36 Although the ex-
pression of the embryonic εy and βh1 globin genes is unaffected by the absence of EKLF, 
the low expression rate of the adult βmaj-globin gene in these cells is EKLF-dependent.39 
Furthermore, LacZ reporter transgenes have been used to demonstrate that EKLF can act as 
a transcriptional activator in embryonic erythropoiesis.38
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The fatal anemia caused by the absence of β-type globin protein in definitive erythro-
cytes, can not be rescued by expression of exogenous γ-globin (the human fetal β-type 
globin) despite an efficient production of hybrid α
2
γ
2
 hemoglobin.29 Moreover, Lim et 
al. demonstrated that EKLF-/- ES cells injected into blastocysts do not contribute to the 
mature erythrocyte compartment, although EKLF-/- cells were found as erythroid progeni-
tors. This phenotype was ameliorated but not completely rescued by γ-globin expres-
sion in these EKLF-/- cells.22 The failure of γ-globin to restore hemoglobin synthesis and 
maturation of erythroid progenitors could be due to a failure in heme synthesis. Heme 
synthesis is tightly coupled to globin gene expression.26 Heme is synthesized from suc-
cinyl CoA and glycine in seven enzymatic steps. It has been suggested that EKLF plays 
a role in the control of expression of some of these genes.37 Two critical enzymes of 
the heme synthesis pathway, Alas2 and Pbgd, contain potential EKLF binding sites.32,35 
Alas2, the erythroid-specific isoform of Alas, is upregulated during erythroid differentia-
tion.10 Expression of Alas2 is critical for erythropoiesis and cannot be compensated for 
by expression of Alas1.42
In addition, EKLF may regulate other genes that are of vital importance in definitive 
erythropoiesis. To study the role of EKLF in erythropoiesis and identify novel EKLF-
dependent genes, we employed in vitro cultures of primary erythroid progenitors that 
undergo a synchronous differentiation program.6,40 Progenitors from mouse fetal livers 
proliferate in serum-free medium under the control of Erythropoietin (Epo), Stem Cell 
Factor (SCF) and the glucocorticoid hormone dexamethasone (Dex). When exposed to 
Epo in absence of SCF and Dex, the cells undergo synchronous terminal differentia-
tion. Differentiation of wild type progenitors mimics in vivo erythropoiesis as the cells 
undergo three to four rapid cell divisions accompanied by a decrease in cell size and the 
accumulation of hemoglobin. Finally the cells expel their nucleus.40 In addition, erythroid 
genes are expressed in the appropriate temporal order during this process.6 This differen-
tiation model of primary cells provides a unique opportunity to study gene expression in 
the absence of EKLF.
In this paper we describe the phenotype of differentiating primary definitive erythrocytes in 
the absence of EKLF. Our data suggest that EKLF is dispensable for erythropoiesis up to the 
pro-erythroblast stage, but is essential for completing the terminal differentiation program. 
We demonstrate that EKLF is required for the activation of erythroid-specific genes that are 
important for stabilization of the cells. Furthermore, we show that expression of these novel 
EKLF-dependent genes is severely reduced in primitive erythroid cells, strongly indicating 
that EKLF is a positive regulator of endogenous genes in these cells. We find morphologi-
cal abnormalities in EKLF-/- primitive cells that are consistent with the reduced expression 
of these genes. Collectively, our data provide an explanation for the hitherto unexplained 
severity of the EKLF null phenotype in definitive cells. The genes identified in this study 
are good candidates for modifier genes affecting the severity of the clinical symptoms of 
thalassemia and sickle cell anemia patients.3,41
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Results
EKLF is required for the in vitro differentiation of primary progenitors
To study the role of EKLF in definitive erythropoiesis, we expanded erythroid progeni-
tors from fetal livers and studied their expansion and differentiation kinetics.6,40 E12.5 fetal 
livers of wild type and EKLF-/- embryos were resuspended in serum-free medium supple-
mented with Epo (1U/ml), SCF (100ng/ml) and Dex (10-6M) and erythroid progenitors were 
expanded for 10 days. The absence of EKLF did not influence the growth proliferation ca-
pacity of the cultured progenitors. EKLF-/- cells proliferated with similar vigour as wild type 
cells (data not shown). Differentiation of the cultures was initiated by replacing the renewal 
factors SCF and Dex with transferrin and high concentrations of Epo (10U/ml). For the 
wild type erythroid progenitors this resulted in the execution of the terminal differentiation 
program, which is characterized by three to four accelerated ‘differentiation’ divisions, cell 
size reduction, accumulation of hemoglobin and finally enucleation. Although EKLF-/- cells 
proliferated normally, they failed to undergo normal terminal differentiation (Fig. 1). First, 
the size of wild type cells decreased significantly. After 48 hours of differentiation, enucle-
ated cells with a diameter of about 5 µm started to appear. In absence of EKLF, the cell size 
distribution barely changed upon induction of differentiation and the cells failed to undergo 
enucleation (Fig. 1a). Second, wild type cells accumulated large amounts of hemoglobin 
after 24 hours of differentiation. In the absence of EKLF however, the amount of hemo-
globin formed was 10-fold lower than in wild type cells (Fig. 1b). Third, cytospins of the 
differentiating cultures show that there are no morphological differences between wild type 
and EKLF-/- cells under renewal conditions (T=0; Fig. 1c). Upon induction of differentia-
tion, however, wild type cells showed all hallmarks of differentiation such as decreased cell 
size, hemoglobin accumulation and enucleated cells, while the EKLF-/- progenitors initially 
retained a large cell size. Eventually, their nuclei became pycnotic (Fig. 1c). In conclusion, 
the data show that the phenotype of EKLF-deficient mice28,30 is not due to a failure of 
EKLF-deficient erythroid progenitors to expand, but that EKLF is specifically required to 
execute the terminal differentiation program. Furthermore, our results validate the use of 
this culture system for the detection of EKLF-dependent genes.
TER-119 positive erythroid cells are lacking in EKLF-/- fetal liver
The TER-119 specific antibody is widely used to detect and enrich erythroid cells. This 
antibody specifically stains erythroid cells that are well advanced in terminal differentia-
tion. TER-119-positive cells show no erythroid blast-forming unit (BFU-E) and erythroid 
colony-forming unit (CFU-E) activities, and therefore represent cells at later differentiation 
stages.17 We have used the TER-119 antibody during our studies of erythropoiesis in EKLF 
null mice. Cells of E12.5 fetal livers were analysed by FACS using the TER-119 antibody, 
and 7-amino-actinomycin D (7-AAD) as a marker for dead cells. In wild type fetal livers, 
the majority of the cells were positive for TER-119, and negative for 7-AAD (~66%) (Fig. 
2). However, in EKLF-/- fetal livers, <1% of the cells were TER-119 positive. In liver cells 
of heterozygous fetuses, the percentage of TER-119 positive, 7-AAD negative cells was 
reduced (~49%) compared to the wild type fetal livers. We also tested embryonic blood of 
E11.5 and E12.5 fetuses for TER-119 staining. In wild type fetuses ~75% of the blood cells 
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were TER-119 positive, 7-AAD negative. In contrast to the EKLF null fetal liver cells, a 
subpopulation of the EKLF null embryonic cells was TER-119 positive, although this frac-
tion was strongly reduced (~20%). Embryonic blood of heterozygous fetuses also contained 
a reduced number of TER-119 positive cells (~41%) compared to wild type blood (Fig. 2). 
We conclude that definitive cells in absence of EKLF do not express the antigen surface 
marker recognized by TER-119 and that fewer embryonic blood cells express this antigen 
in the absence of EKLF.
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Figure 1. Differentiation of primary erythroid progenitors
a Cell size distribution of wild type and EKLF-/- erythroblast cultures during differentiation. The size 
of wild type cells decreases during differentiation and after 48 hours enucleated cells appear, indicated 
by an arrow. The cell size of EKLF-/- cells hardly decreases during differentiation. b Hemoglobin per 
cell volume was measured with intervals of 12 h. in wild type and EKLF-/- cultures after induction for 
differentiation. c Morphological analysis of wild type and EKLF-/- erythroblasts during differentiation. 
Aliquots of the cultures were cytocentrifuged onto glass slides and stained with both cytological dyes 
and with neutral benzidine for hemoglobin (brownish stain). The absence of EKLF does not affect 
progenitors (T=0). At T=36 a decrease of cell size compared to cells at T=0 is observed in the wild 
type culture, but not in the EKLF-/- culture. Only in the wild type cultures, hemoglobin is detected, first 
at T=54 (arrowheads), and these cells can complete the terminal differentiation to enucleated erythro-
cytes (black arrows). EKLF-/- cells do not accumulate hemoglobin and their nuclei become pycnotic 
(red arrows). Original magnification is 100X. T = time in hours; KO = knockout.
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Reduced expression of genes involved in heme synthesis in EKLF-/- erythroid cells
The in vitro expansion and synchronous induction of terminal differentiation of erythroid 
progenitors provides a unique opportunity to study EKLF-dependent gene expression. In 
addition to insufficient β-globin synthesis, the failure of EKLF-deficient cells to accumulate 
hemoglobin could be due to reduced heme synthesis, as both processes are tightly linked. 
Heme is synthesized from succinyl CoA and glycine in seven enzymatic steps, catalysed by 
aminolevulinic acid synthase (Alas), aminolevulinate dehydratase (Alad), porphobilinogen 
deaminase (Pbgd), uroporphyrinogen decarboxylase (Urod), coproporphyrinogen oxidase 
(Cpox), protoporphyrinogen oxidase (Ppox) and ferrochelatase (Fech) respectively. We 
performed real time PCR experiments to detect the expression of these genes in in vitro 
expanded erythroid progenitors 36 hours after induction of differentiation and in fresh 
E12.5 fetal livers (Fig. 3a). Expression of Alas2 and Alad is significantly decreased in the 
absence of EKLF both in in vitro expanded progenitors and in fetal livers. Because the first 
step catalysed by Alas2 is the rate-limiting step in the heme synthesis pathway, we were 
particularly interested in its expression. Fig. 3b shows the expression pattern of Alas2 dur-
ing the first 36 hours of differentiation in wild type and EKLF null cells. As expected, the 
gene is upregulated during erythroid differentiation of wild type cells. Although the gene is 
also upregulated in the absence of EKLF, the expression is reduced compared to wild type 
cells. Furthermore, expression of Alas2 in EKLF-/- fetal livers is strongly reduced compared 
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Figure 2. FACS analysis
Fetal liver- and embryonic 
blood cells of wild type, 
heterozygous and EKLF-/- em-
bryos were stained with TER-
119 and 7-AAD and analysed 
by FACS. Numbers give the 
average of TER-119 positive, 
7-AAD negative cells in per-
centage of the counted cells. 
The standard deviations are 
included.
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to wild type fetal livers. No obvious difference in Alas2 expression is found between wild 
type and heterozygous fetal livers. We conclude that the expression of enzymes involved 
in heme synthesis is not completely dependent on EKLF. However, dysregulation of the 
rate-limiting enzyme Alas2 might contribute to the failure of EKLF-deficient cells to ac-
cumulate hemoglobin.
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Figure 3. Expression of genes 
involved in heme synthesis in 
EKLF-deficient erythroid cells
a Expression of genes involved 
in heme synthesis was measured 
by real time PCR on cDNA of 
wild type and EKLF KO cultures 
36 hours after induction of eryth-
roid differentiation, and of fresh 
E12.5 fetal livers. Values were 
normalised to Hprt. The wild 
type values were set to 100% in 
grey, EKLF KO values in black. 
Error bars indicate the standard 
deviation between experiments. 
b Northern blot showing the ex-
pression of Alas2 in differentiat-
ing wild type and EKLF KO cultures and in E12.5 fresh fetal livers of wild type, heterozygous and EKLF 
KO embryos. Gapdh was used as a loading control. Numbers indicate time of differentiation in hours. 
wt = wild type; +/- = heterozygous for the EKLF knockout; KO = EKLF knockout. Abbreviations for the 
heme synthesis enzymes are given in the text.
Micro-array screening reveals EKLF-dependent genes
The failure to upregulate Alas2 and βmaj globin gene expression is consistent with the 
observation that EKLF-/- mice lack functional definitive erythrocytes. However, the in vitro 
differentiation of expanded erythroid progenitors indicates that differentiation of EKLF-
deficient progenitors is impaired prior to hemoglobin accumulation (Fig. 1c). To find other 
genes that may be regulated by EKLF we performed gene expression profiling of primary 
fresh E12.5 fetal liver cells and in vitro expanded and differentiated cells. We used cDNA 
micro-arrays made by the BioOptics department at the IMP in Vienna, containing approxi-
mately 17,000 different EST sequences (representing individual genes once or maximally 
twice). These sequences were obtained from ‘the German Genome Initiative’ in Berlin. 
Furthermore, we used custom-made micro-arrays containing approximately 9000 cDNAs 
enriched for erythroid- and T cell-specific transcripts.18 This custom-made micro-array has 
the advantage that it contains multiple copies of erythroid-specific genes, thus enabling 
multiple measurements of the expression of these genes in a single experiment. Primary 
progenitors of wild type and EKLF-/- fetal livers were expanded for 10 days and subse-
quently induced to differentiate. RNA was collected from non-induced cells and from cells 
12 hours after induction. RNA was also isolated from fresh E12.5 wild type and EKLF-/- 
fetal livers. cDNAs were generated from these RNAs, Cy5- or Cy3-labelled and hybridised 
a
b
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to both 9K and 17K micro-arrays. The Cy3/Cy5 ratios were calculated for each spot as 2log 
value. Table 1 lists these values for genes that appeared to be regulated by EKLF. The larg-
est differences in gene expression between wild type and EKLF-/- RNA samples were found 
in fresh fetal livers. Spots representing genes involved in heme synthesis did not give high 
ratios between wild type and EKLF-/- samples, which could be due to the fact that these 
genes are only upregulated later in differentiation. The erythroid-specific Alas2 gene was 
not present on the micro-arrays used. Many of the genes that appeared to be upregulated 
by EKLF can be classified as erythroid-specific and/or cell membrane-specific. Amongst 
the erythroid-specific genes is the known EKLF target gene βmaj globin. As expected, high 
ratios are found since the expression of the βmaj gene is dependent on EKLF.28,30
Regulation of target genes by activating EKLF
To study the direct involvement of EKLF in the expression of a number of these listed 
genes, we made use of a tamoxifen (4-OHT) inducible fusion protein consisting of EKLF 
and a modified estrogen-receptor ligand-binding domain (EKLF-lbd).7 In transgenic mice 
this construct is expressed under the control of an α-globin promoter. We wished to demon-
strate expression of the target genes by activating the EKLF-lbd protein. We isolated EKLF-
/- fetal liver cells carrying the EKLF-lbd transgene and cultured the cells for 16 hours in dif-
ferentiation medium. To demonstrate direct EKLF-dependent expression of the genes, we 
added the protein inhibitor cycloheximide (CHX) to the cultures. CHX prevents synthesis 
of new proteins. Therefore, gene expression of these cultured cells cannot be due two sec-
ondary pathways. Gene expression of these cultures was studied by real time quantitative 
PCR. The differences in PCR cycles at which the PCR products reach the threshold level 
are shown in Figure 4. The expression of βmaj, AHSP, Kcnn4 and Epb4.9 are upregulated 
after 16 hours of differentiation in the presence of 4-OHT and CHX, indicated with the 
dark bars. These genes are also upregulated in the absence of CHX (light bars). Ca1 may be 
downregulated by EKLF (Table 1). However, in these experiments Ca1 is only downregu-
lated in the absence of CHX, indicating that EKLF is indirectly involved in its downregula-
tion. Next, we focussed our attention on two newly identified EKLF-dependent genes in the 
erythroid-specific- and membrane-specific categories, AHSP and Epb4.9 respectively.
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Figure 4. Gene regulation by activating EKLF
EKLF null fetal liver cells carrying an EKLF-
lbd transgene were cultured for 16 hours. Gene 
expression was measured by real time quantita-
tive PCR. The graph shows the difference in 
PCR cycles at which the PCR products reach the 
threshold level between T=0 (fresh liver cells) 
and T=16 (cultured cells). The medium of the 
cultured cells contained 4-OHT with (dark bars) 
or without (light bars) CHX. Error bars indicate 
SEM.
Chapter three
60
carbonic anhydrase 1 Car1
pyruvate kinase, muscle Pkm2
-1.2
-1.6
-1.3
-1.1
-2.5
-1.7
coagulation factor II (thrombin) receptor F2r
enolase 1, alpha non-neuron Eno1
heme oxygenase (decycling) 2 Hmox2
phosphoglycerate mutase 1 Pgam1
RIKEN cDNA 1110014J01 gene 1110014J01Rik
kelch domain containing 3 Klhdc3
24-dehydrocholesterol reductase Dhcr24
RIKEN cDNA 6720456B07 gene 6720456B07Rik
thrombospondin 1 Thbs1
guanosine monophosphate reductase Gmpr
ethanolamine kinase 1 Etnk1
-1.0
0.0
0.0
-0.1
-0.3
0.1
-0.3
0.0
0.1
-0.7
-0.7
-0.4
-0.4
-0.2
-0.1
0.0
-0.1
0.3
0.1
-0.4
-0.2
-0.5
-1.3
-1.2
-2.9
-1.2
-2.3
-1.8
-1.9
-2.1
-2.5
-1.6
-1.6
metastasis suppressor 1 Mtss1 0.2 -0.1 -1.6
Genes down-regulated in EKLF KO Symbol Cultured cells
T=0 T=12
Fetal
liver
Heme synthesis
solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 Slc3a2
solute carrier family 2 (facilitated glucose transporter), member 1 Slc2a1
solute carrier family 22 (organic cation transporter), member 4 Slc22a4
solute carrier family 43, member 1 Slc43a1
Kell blood group Kel
CD24a antigen Cd24a
transferrin receptor Tfrc
intercellular adhesion molecule 4, Landsteiner-Wiener blood group Icam4
Other
protease, serine, 25 Prss25
sin3 associated polypeptide Sap30
interferon-induced protein with tetratricopeptide repeats 3 Ifit3
ubiquitin associated domain containing 1 Ubadc1
unc-84 homolog A (C. elegans) Unc84a
RIKEN cDNA 1110063G11 gene 1110063G11Rik
RIKEN cDNA 1200006I17 gene 1200006I17Rik
monoglyceride lipase Mgll
cat eye syndrome chromosome region, candidate 2 homolog (human) Cecr2
lectin, galactose binding, soluble 1 Lgals1
myeloid differentiation primary response gene 116 Myd116
guanine nucleotide binding protein, alpha inhibiting 2 Gnai2
guanine nucleotide binding protein, alpha inhibiting 2 Gnai2
mitogen activated protein kinase kinase 5 Map2k5
hypothetical Guanylate-kinase-associated protein Dlg7
CCR4-NOT transcription complex, subunit 7 Cnot7
Mus musculus RIKEN cDNA 2700084L06 gene 2700084L06Rik
peroxiredoxin 2 Prdx2
microsomal glutathione S-transferase 3 Mgst3
nuclear factor of kappa light chain gene enhancer in B-cells inhibitor, alpha Nfkbia
glutathione peroxidase 4 Gpx4
Genes up-regulated in EKLF KO
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-0.2
0.2
0.5
-0.1
0.3
0.2
-0.1
0.9
0.2
0.4
0.4
0.8
0.1
-0.4
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0.7
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0.7
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0.4
0.7
0.4
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0.6
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-0.6
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0.4
0.4
0.6
0.8
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0.3
0.7
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0.9
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0.4
1.0
0.6
0.3
1.0
2.9
1.5
1.7
1.8
1.9
1.5
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1.7
4.7
2.1
2.1
1.6
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1.9
1.8
1.4
1.8
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1.4
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3.1
3.6
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1.3
1.2
1.9
1.6
1.4
aminolevulinic acid synthase 1 Alas1
hydroxymethylbilane synthase/porphobilinogen deaminase Hmbs/PBGD
uroporphyrinogen decarboxylase Urod
coproporphyrinogen oxidase Cpox
protoporphyrinogen oxidase Ppox
ferrochelatase Fech
Erythroid specific
hemoglobin, beta adult major chain Hbb-b1
Hemoglobin, beta adult major chain Hbb-b1
hemoglobin Z, beta-like embryonic chain Hbb-bh1
hemogen Hemgn
Alpha Hemoglobin Stabilizing Protein Eraf
Cell membrane
erythrocyte protein band 4.9 Epb4.9
K intermediate/small conductance Ca -activated channel, subfamily N, member 4+ 2 + Kcnn4
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Alpha Hemoglobin Stabilising Protein
AHSP (Eraf, Edrf) is an abundant erythroid-specific protein that forms a stable complex 
with free α-globin.16 An imbalanced production of α- and β-globin, as observed in tha-
lassemia patients, can lead to precipitation of the free globins forming cytotoxic Heinz 
bodies.27 By binding free α-globin, AHSP prevents α-globin denaturation and precipitation. 
AHSP was represented 10 times on the erythroid-specific micro-array chip and the average 
ratio between wild type and EKLF-/- expression at T=0 was 2 fold, at T=12 6 fold and in 
uncultured fetal livers 12 fold. Thus, AHSP expression appears to be consistently down-
regulated in EKLF-/- erythroid cells.
The micro-array data for AHSP expression were confirmed by Northern blot analysis 
(Fig. 5a). AHSP mRNA is not detected in undifferentiated wild type progenitors (T=0), but 
increases to high levels during differentiation. However, in the absence of EKLF AHSP is 
not detected at any time during differentiation. Similarly, AHSP is not expressed in uncul-
tured EKLF-/- E12.5 fetal livers. No obvious difference in expression in EKLF+/- compared 
to wild type uncultured fetal livers is found.
Since the expression of AHSP appears to be strongly dependent on EKLF, we were inter-
ested in the expression of AHSP in primitive erythroid cells in embryonic blood. Primitive 
cells express α-globin and therefore expression of AHSP can be expected. Notably, EKLF 
is also expressed in these cells, although to date, no endogenous EKLF-dependent genes 
have been described in primitive cells. We performed Northern blot analysis for AHSP on 
RNA isolated from EKLF+/+, +/- and -/- primitive blood cells. Figure 5a (right panel) shows 
that AHSP expression is readily detected in wild type and heterozygous primitive blood 
cells. However, no expression of AHSP is observed in the absence of EKLF (Fig. 5a).
In adult blood of AHSP-/- mice, precipitates of α-globin are detected as Heinz bodies.16 
Because of the absence of β-globin in EKLF-/- fetuses, the presence of Heinz bodies in 
erythrocytes would not provide useful information on the consequences of the absence of 
AHSP. The excess of α-globin chains would result in the formation of globin chain pre-
cipitates regardless of the functional status of AHSP. However, since EKLF has no effect 
on the expression of the embryonic globin genes, we examined whether precipitates could 
be found in EKLF-/- primitive blood cells. E12.5 yolk sacs (7 wild type or EKLF+/- and 8 
EKLF-/-) were fixed, embedded in epon and 1 µm sections were stained with toluidine/
methylene blue. We observed blue spots, generally located in apparent close proximity to 
the cell membrane, only in the EKLF-/- yolk sacs (Fig. 5b). These blue spots most likely rep-
resent inclusion bodies resulting from the precipitation of α-globin chains in the absence of 
Table I. Genes that are differentially expressed in the absence of EKLF
Gene expression in wild type and EKLF knockout (KO) cultured cells at T=0 
and T=12 hours after differentiation, and in wild type and EKLF KO fetal 
livers was determined with cDNA micro arrays. Values are the 2log of the 
ratio wild type/EKLF KO. The average of values is taken when genes are 
represented more than once on the chips. The list includes values from the 17k 
(circles) and the erythroid-enriched 9k (triangles) micro-arrays. Genes with 
ratios higher than 1.2 or lower than -1.2 in fetal livers, and genes involved in 
heme synthesis, are displayed.
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AHSP. Morphologically they appear to be analogous to the Heinz bodies found in definitive 
erythrocytes of AHSP-deficient mice.16 Collectively, our results demonstrate that EKLF 
positively regulates the expression of AHSP in both definitive- and primitive erythroid 
cells. Absence of AHSP in EKLF-/- primitive blood cells results in the formation of α-globin 
precipitates and, together with the formation of such precipitates in definitive blood cells, 
may contribute to the severity of the phenotype of the EKLF knockout.
Figure 5. Ahsp expression in 
EKLF null erythroid cells
a Northern blot showing accu-
mulation of Ahsp in wild type 
cells during differentiation, 
but not in EKLF-/- cultures. 
Furthermore, Ahsp expression 
is EKLF-dependent in E12.5 
fetal livers and in embryonic 
blood. Gapdh was used as a 
loading control. b Apparent in-
clusion bodies detected as dark 
spots (indicated by arrows) in 
EKLF-/- embryonic blood cells 
in toluidine/methylene blue 
stained semi-thin sections of 
fixed E12.5 yolk sacs. These 
dark spots were not detected 
in wild type embryonic blood 
cells. Original magnification 
is 100X. Other details are as 
for Fig. 3.
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Erythrocyte protein band 4.9
Epb4.9 is the most differentially expressed membrane-specific gene found in the micro-
array experiments comparing wild type- and EKLF-/- fetal livers (Table I). Epb4.9, or 
dematin, is an actin-binding and bundling protein of the erythrocyte membrane skeleton. 
It is required for the maintenance of the erythrocyte shape and mechanical properties of 
the erythrocyte membrane.15 Epb4.9 expression is not limited to erythroid cells,34 but mice 
expressing a truncated form of the protein (dematin headpiece null mice) show signs of 
compensated anemia and spherocytosis,15 indicating that erythroid cells require this pro-
tein. To confirm the micro-array data, we performed a Western blot with whole cell protein 
extract from E12.5 fetal livers. Epb4.9 expression is completely EKLF dependent (Fig. 6a). 
Interestingly, Epb4.9 expression in primitive blood cells is also dependent on the presence 
of EKLF (Fig. 6a). Since Epb4.9 is required for the stability of the erythrocyte membrane,15 
we analyzed the morphology of EKLF-/- primitive cells  on cytospins of blood isolated from 
E12.5 embryos (Fig. 6b). The membrane of wild type cells appears smooth and, in general, 
the cells are round-shaped (arrowheads). In contrast, the membranes of EKLF-/- cells appear 
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to be wrinkled and the cells are deformed (arrows). This suggests that the cell membrane 
is less stable and malleable, very similar to the morphological abnormalities observed in 
erythrocytes of Epb4.9 mutant mice.15 We conclude that the expression of the Epb4.9 gene 
in erythroid cells is strictly dependent on the presence of EKLF. The lack of Epb4.9 expres-
sion adversely affects the functioning of the erythroid cell membrane, thus contributing to 
the severity of the EKLF knockout phenotype.
Discussion
EKLF is active late in the erythroid differentiation program
In primary erythroid cultures we found that that EKLF is dispensable for the expansion of 
erythroid progenitors. However, activation of EKLF-dependent genes is required to ex-
ecute the terminal differentiation program completely. Upon induction of differentiation 
wild type cells rapidly differentiate to hemoglobinised, enucleated erythrocytes, whereas 
EKLF-/- progenitors initially retain their blast-phenotype, fail to enucleate and their nuclei 
finally become pycnotic. This is in agreement with the observation that EKLF-/- ES cells 
contribute to erythroid progenitors but not to the mature erythrocyte compartment in chi-
meric mice.22 It was postulated that this phenotype was due to the lack of β-globin expres-
Epb4.9
eIF2
wt wtKO KO
Liver
Embryonic
blood
Wild type EKLF KO
Figure 6. Epb4.9 expression in EKLF knockout erythroid cells
a Western blot of whole cell protein extract. Expression of Epb4.9 is detected in E12.5 fetal livers and 
in embryonic blood of wild type embryos, but not in EKLF-/- embryos. Antibody against translation 
elongation factor eIF2α is used as a loading control. b Cytospins of primitive blood cells, stained with 
neutral benzidine and histological dyes, show-
ing morphological abnormalities of EKLF KO 
cells. Membranes of wild type blood cells ap-
pear smooth and the cells are round shaped, 
indicated by arrowheads. The membranes of 
EKLF KO blood cells are wrinkled and the 
cells are deformed, indicated by arrows. Other 
details are as for Fig. 3.
a
b
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sion. However, expression of γ-globin in these cells only partially rescued the phenotype, 
suggesting that EKLF regulates more genes that are important for erythroid differentiation. 
Here, we describe a number of novel EKLF-dependent genes that have important functions 
in the physiology of erythroid cells. In definitive erythroid cells these genes display an 
expression pattern similar to that of β-globin, since they become highly expressed late in 
erythroid differentiation. Thus, EKLF is an activator of essential erythroid genes that are 
upregulated during terminal erythroid differentiation.
Is TER-119 a target gene of EKLF?
TER-11914 is an antibody that specifically recognizes erythroid cells that have progressed 
in the differentiation hierarchy beyond the progenitor stage.17 Its antigen is associated with 
glycophorin A, although it does not bind it directly.17 The gene and function of the protein 
are unknown. The finding that no EKLF-/- fetal liver cells express this antigen raises the 
question whether its gene is a direct target of EKLF or whether the absence of EKLF causes 
a defective terminal differentiation of erythroid cells. Since TER-119 positive primitive 
blood cells are found in EKLF-/- fetuses, a defect in differentiation is the most likely expla-
nation. This is further supported by the fact that the intensity of TER119 staining (Fig. 2) is 
not decreased in EKLF-/- primitive blood cells. Hence, the expression per cell is not affected 
by EKLF but only the number of cells expressing the TER-119 antigen is decreased. 
Interestingly, the percentage of TER-119 positive cells in heterozygous fetal livers cells 
and in heterozygous embryonic blood cells is lower than in wild type fetuses. This can be 
explained by a shortened life span of the cells, caused by reduced expression of EKLF, 
concordant to EKLF null cells.22 A reduced expression of some EKLF target genes (e.g. 
AHSP and Epb4.9) may cause this shortened life span. This would imply that heterozygous 
cells are more affected by the presence of only a single EKLF gene than previously thought. 
However, it remains to be considered whether the TER119 gene is a direct target of EKLF.
Heme synthesis enzymes
The effect of the absence of EKLF on the expression of heme synthesis genes is rather sub-
tle. Apparently these genes are not completely dependent on the presence of EKLF. This is 
not surprising since the enzymes of the heme synthesis pathway are ubiquitously expressed. 
Heme is an important molecule in many metabolic processes. Cell growth and in particu-
lar mRNA translation are controlled by the availability of nutrients and mitogenic factors, 
and also by the availability of heme. Heme-regulated eIF2α kinase (HRI) phosphorylates 
and inactivates eukaryotic initiation factor 2α (eIF2α).4 HRI kinase activity is inhibited by 
heme, in a mechanism that co-ordinates heme- and globin synthesis.12 In E12.5 EKLF-/- fe-
tal livers we did not observe an elevated phosphorylation of eIF2α compared to wild type 
fetal liver (data not shown), indicating that heme synthesis is still sufficient for the basic 
metabolic requirements of erythroblasts.
However, hemoglobin synthesis in differentiating erythroblasts requires synthesis of heme 
at a level that largely exceeds that in normal cells. Therefore, erythroblasts express an eryth-
roid-specific isoform of Alas, the rate-limiting enzyme in heme synthesis. Alas2-deficiency 
completely abrogates hemoglobin synthesis.13 In contrast to the ubiquitously expressed 
Alas1, the erythroid specific Alas2 is controlled by the erythroid specific transcription 
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factors Gata1, EKLF and NF-E2 that also regulate β-globin expression.19 In addition, the 
appropriate expression of Alas2, but not Alas1, is controlled by the availability of iron at 
the level of mRNA translation.24 Notably, reticulocytes contain high levels of HRI, requir-
ing high concentrations of heme to allow mRNA translation to proceed. Thus, a network 
of control mechanisms ensures the coordinate expression of the components required for 
the synthesis of hemoglobin. This may explain why EKLF-deficiency does not completely 
inhibit Alas2 and β-globin gene expression, yet almost fully abrogates hemoglobin produc-
tion in differentiating erythroblasts.
EKLF is functional in primitive blood cells
In addition to the heme synthesis genes, we have focussed on two genes, AHSP and Epb4.9, 
that appear to be strictly dependent, for their expression in definitive erythroid cells, on 
EKLF. Interestingly, these genes are also dependent on EKLF for expression in primitive 
cells. This strongly suggests that EKLF functions as a positive regulator in both definitive 
and primitive cells. Previously, no abnormalities have been described for EKLF null em-
bryonic cells. However, the absence of AHSP and Epb4.9 is likely to cause the observed 
phenotype of primitive EKLF-deficient cells, i.e. the presence of protein precipitates remi-
niscent of Heinz bodies and apparent membrane instability. Mice lacking AHSP are viable, 
but Heinz bodies are present in definitive erythrocytes caused by precipitated -globin 
chains.16 We found similar inclusion bodies in EKLF null embryonic blood cells. Since 
α-globin synthesis precedes β-globin synthesis,5 the nascent α-globin proteins have to be 
stabilised until they are incorporated in hemoglobin. In the absence of AHSP, α-globin 
precipitates inflict membrane damage on the erythrocytes leading to an increased turnover 
of the cells.16 
Epb4.9 plays an important role in the stability of the erythroid membrane skeleton. Eryth-
rocytes of Epb4.9 mutant mice have a more fragile membrane skeleton and reduced de-
formability, caused by reduced association of spectrin and actin to the plasma membrane.15 
Embryonic blood cells lacking EKLF and therefore lacking Epb4.9 expression, appear to 
have a similarly weakened cell membrane. Furthermore, this phenotype can be aggravated 
by the lack of AHSP. Although AHSP- and Epb4.9- mutant mice are viable, the of lack of 
expression of both genes, as is the case in the absence of EKLF, is likely to further reduce 
the half life of erythrocytes, consistent with observations on EKLF-/- adult erythrocytes.22 
Notably, EKLF-/- primitive blood cells appear to function sufficiently since EKLF-/- em-
bryos die only at the time when they become dependent on definitive blood cells. This sug-
gests that the large, nucleated primitive cells are relatively flexible in their ability to cope 
with disturbed functionality, compared with the highly specialized enucleated definitive 
cells. This, in addition to the fact that they last for only 4 or 5 days, may explain why the 
phenotype of EKLF-/- primitive cells is subtle, allowing them to carry out their essential 
tasks during embryogenesis.
Additional EKLF-dependent genes
Our studies focussed on EKLF-dependent genes that are particularly informative on the 
role of EKLF in primitive and definitive erythropoiesis. However, the micro-array analysis 
revealed a number of additional differentially expressed genes (Table I). Among those is 
Chapter three
66
the transferrin receptor that transports iron into the cells. Reduced expression of the trans-
ferrin receptor is in line with impaired heme and globin synthesis. Peroxiredoxin 2 (Prdx2) 
is an important enzyme in the protection against oxidative stress. In particular, erythroid 
cells deficient in Prdx2 age prematurely. This is accompanied by membrane instability and 
the accumulation of Heinz bodies. As a result, Prdx2-deficient mice suffer from hemolytic 
anemia.21 
Some of the differentially expressed genes are expressed at increased levels in EKLF-/- eryth-
roblasts such as carbonic anhydrase 1 (Car1; Table 1). The ubiquitously expressed Car1 
gene is downregulated during erythroid differentiation, when it is replaced by the erythroid-
specific isoform Car2. This suggests that EKLF may function in transcriptional repression. 
The mechanism by which this is achieved remains to be investigated, because by default 
genes are shut down during terminal erythroid differentiation owing to progressing general 
heterochromatization of the genome. It would appear that EKLF counteracts this general 
shut down of transcription at loci that are of particular importance for erythroid matura-
tion.
Synopsis
Collectively, we have shown that EKLF is dispensable for the generation and expansion 
of erythroid progenitors, but that it is essential for the differentiation of erythroid progeni-
tors to functional erythrocytes. EKLF regulates hemoglobin synthesis through control of 
β-globin gene expression, but it also controls expression of enzymes of the heme synthesis 
pathway, for example the erythroid-specific, rate-limiting enzyme Alas2. The failure of 
EKLF-/- progenitors to undergo terminal differentiation suggests that EKLF regulates genes 
with an important function in the differentiation-specific gene expression program (Fig. 7). 
Impaired upregulation of these genes during terminal differentiation contributes to the phe-
notype of EKLF-/- cells. From several putative EKLF-dependent genes identified by mRNA 
profiling, we have shown that the expression of AHSP and Epb4.9 is strictly dependent on 
the presence of EKLF, not only in definitive- but also in primitive erythroid cells. Lack of 
expression of these genes adversely affects the functional properties of erythroid cells.15,16 
In conclusion, our data show that EKLF coordinates the expression of a panel of proteins 
involved in differentiation of erythroid progenitors, and the maturation and survival of 
erythrocytes. These results explain why expression of exogenous γ-globin only partially 
restores the observed shortened lifespan of EKLF-/- adult erythrocytes, and fails to rescue 
definitive erythropoiesis in EKLF-/- mice.22,29 In these scenarios EKLF-/- erythroid cells still 
have major defects even if the ratio of α- and β-like globin chains has been corrected. The 
genes identified in this study are good candidates for modifier genes affecting the severity 
of disease in thalassemia and sickle cell anemia patients.3,11,41 Furthermore, our data suggest 
that mutations affecting the function of the EKLF transcription factor would have a major 
impact on the severity of these diseases. It is interesting to note that β-thalassemia result-
ing from dysfunction of the EKLF gene has not been found in the human population yet.41 
We suggest that a complete abrogation of EKLF function would not be compatible with 
post-embryonic life, because fetal liver erythropoiesis would be dysfunctional, even though 
γ-globin expression levels should be normal and the severe β-thalassemia observed in mice 
should not occur during human fetal development. 
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Materials and methods
Cultivation of mouse erythroid progenitors
Fetal livers of E12.5 mouse embryos were disrupted and seeded into Stem-Pro-34TM medi-
um supplemented with human recombinant erythropoietin (Erypo, Cilag AG, Switzerland, 
1 U/ml), murine recombinant stem cell factor (SCF, R&D Systems, Minneapolis, MN, 
USA, 100 ng/ml) and dexamethasone (Dex, Sigma, 10-6 M).40 The cultures of erythroid 
progenitors were subjected to daily partial medium changes and addition of fresh factors. 
Cell numbers and size distributions were determined daily, using an electronic cell counter 
(CASY-1, Schärfe-Systems, Reutlingen, Germany). Progenitors were enriched through Fi-
coll (lymphocyte separation medium, 1078 g/cm3, Eurobio, France) by centrifugation when 
the cultures contained >40% dead and/or differentiated cells as estimated by size distribu-
tion. Cell density was kept at ~2x106 cells/ml.
Terminal differentiation of mouse erythroid progenitors
Progenitors were washed twice in PBS and seeded at 1.5x106 cells/ml in differentiation 
medium (Stem-Pro-34TM medium supplemented with Epo (10U/ml) and iron-saturated hu-
man transferrin (Sigma, 1 mg/ml). Cells were maintained at densities of 2-4x106 cells/ml, 
requiring dilution with fresh medium twice daily between 24 and 50 h. Cell number and 
size distribution was determined using an electronic cell counter. Hemoglobin content was 
quantitated in a photometric assay as described.1 In short, 2–4 x 104 cells were washed 
in PBS, lysed in 20 µl H
2
O, and frozen until further analysis. 100 µl of reagent mix (0.5 
mg/ml o-phenylenediamine (Sigma-Aldrich) and 0.03% H
2
O
2
 in 0.1 M citrate/phosphate 
Figure 7. EKLF regulates genes necessary late in the erythroid differentiation program
The hematopoietic stem cell gives rise to all blood cell types, including the erythroid lineage. In 
the erythroid differentiation program, EKLF is dispensable for the expansion of erythroid progeni-
tors. To complete the differentiation program, EKLF is required for the proper expression of genes 
involved in cell membrane stability (e.g. Epb4.9) and hemoglobin metabolism (e.g. β-globin, heme 
synthesis enzymes, AHSP), in order to enable appropriate terminal differentiation to erythrocytes.
ErythrocyteHematopoietic
Stem Cell
Erythroid
progenitor
EKLF
Hemoglobin metabolism
Cell membrane stability
Terminal differentiationExpansion
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buffer, pH 5.0) was added to thawed samples. The reaction time was kept identical for all 
reactions within each experiment and was stopped after ~2 min. with 20 µl 8 N H
2
SO
4
. The 
492 nm extinction of the reaction product was measured with an ELISA spectrophotometer. 
Extinction/cell volume was taken as a measure for hemoglobin content.
Real-time PCR
The real-time PCR assay was performed on a BIO-RAD Icycler. For the PCR reactions, 
the Eurogentec qPCRTM Corekit for SybrTM Green was used. Reactions were performed in 
25 µl mix as described by the manufacturer. Amplification program: 10 min. 95ºC, 40 cy-
cles of denaturation at 95ºC for 20 sec., annealing and elongation at 60ºC for 45 sec. After 
each elongation step, the fluorescence signal was measured at 75ºC. To confirm amplifica-
tion specificity the PCR products from were subjected to melting curve analysis. Primer 
sequences are as follows: 
Alas2: 5’-CACCTATGCTTAAGGAGCCA-3’ and 5’-CAGAAGCACACAGGAAAGCA-3’, 
Alad: 5’-CTTTGATCTCAGGACTGCTG-3’ and 5’-AACAGCTGCGGTGCAAAGTA-3’, 
Pbgd: 5’-TACTTCTGGCTTCCAAGTGC-3’ and 5’-CAAGGTGAGGCATATCTTCC-3’, 
Urod: 5’-ATCCCTGTGCCTTGTATGCA-3’ and 5’-AGGTTGGCAATTGAGCGTTG-3’ 
Cpox: 5’-CAATTTGAAGCCAGTCCGTG-3’ and 5’-CTGGACTAGAACTCCCTTTG-3’, 
Ppox: 5’-ATTCCAGCTTCAGAGCTCAG-3’ and 5’-TACTGCAGATTCACCACAGC-3’, 
Fech: 5’-ACCAGTGACCACATTGAGAC-3’ and 5’-GGCCTTGGAGAACAATGGAT-3’, 
HPRT: 5’-AGCCTAAGATGAGCGCAAGT-3’ and 5’-ATGGCCACAGGACTAGAACA-3’,
β-globin: 5’-ATGCCAAAGTGAAGGCCCAT-3’ and 5’-CCCAGCACAATCACGATCAT-3’
AHSP: 5’-GGATCAGCAGGTCTTTGATG -3’ and 5’-AGAGTACTCAGCTCTTGCTG-3’
Kcnn4: 5’-AAGCACACTCGAAGGAAGGA-3’ and 5’-TTCCGGTGTTTCAGCCGTA-3’
Epb4.9: 5’-TGCTCAAGACCCAAGGCTTA-3’ and 5’-TCCTATCTGGTTTTGCCTGG-3’
Gapdh: 5’-CCTGCCAAGTATGATGACAT-3’ and 5’-GTCCTCAGTGTAGCCCAAG-3’
CA1: 5’-AGAGTCTGCAGTTCCAGTTC-3’ and 5’-GCCAGGTCATAATTGAGGAC-3’
FACS
Cells from E12.5 fetal livers and E11.5 and E12.5 embryonic blood cells were collected and 
washed in DMEM 10% FCS. They were stained with rat PE conjugated TER-119 antibody 
(Pharmingen) in a 1 in 100 dilution.17 Dead cells were stained with 7-aminoactinomycin-D 
(7-AAD, Molecular Probes BV) at 1 µg/ml. FACS analysis was performed on a Becton 
Dickinson FACScan. Percentages of TER-119 positive, 7-AAD negative cells are averages 
of 3 wt, 4 heterozygous and 3 KO E12.5 livers and 4 wt, 12 heterozygous and 5 KO E11.5 
or E12.5 embryonic blood cells. No significant difference was found in the percentages 
between E11.5 and E12.5 blood.
cDNA array hybridizations and analysis
Total RNA from cultured cells and fetal livers was extracted using TRI REAGENT (Sigma) 
following the manufacturer’s instructions. This RNA was used to hybridise micro-arrays 
containing ~17.000 EST sequences obtained from the ‘German Genome Initiative’ in 
Berlin and a custom-made hematopoietic micro-array containing ~9.000 cDNAs that were 
enriched for erythroid- and T cell–specific cDNAs by subtracting cDNA of expanding I/11 
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cells and quiescent CD4+ T cells from cDNAs prepared from 3T3 fibroblasts and EpH4 
epithelial cells.18 For a single hybridization, 30 µg total RNA was reverse transcribed into 
cDNA using Cy5-UTP or Cy3-UTP (CyDye; Amersham Biosciences). The micro-arrays 
were hybridized and analyzed as described previously.18 The scanning was performed using 
a Genepix 400A scanner (Axon Instruments, Inc.), and the analysis was performed using 
the GenePix program, Microsoft Excel and Access.
Inducible EKLF cultures
Livers were isolated from E12.5 EKLF-/-::EKLF-lbd fetuses. Single cell suspensions were 
cultured for 16 hours in StemPro-34 containing 1% BSA, 1% glutamine, and 10 U/ml EPO, 
but without serum supplement. The EKLF-lbd was activated by supplementing the medium 
with 250 nM 4-hydroxy-tamoxifen with or without 20µg/ml cycloheximide. After 16 hours 
of culture, cells were harvested and RNA was isolated for preparing cDNA.
Western blotting
From wild type and EKLF-/- E12.5 fetuses, livers were disrupted and embryonic blood 
cells washed in PBS/1mM EDTA. The cells were spun down and lysed in RIPA buffer 
(150mM NaCl/1.0% NP-40/0.5% DOC/0.1% SDS/50mM Tris-HCl pH 8.0) supplemented 
with a protease inhibitor cocktail (Sigma). Proteins were separated on 10% SDS-PAGE gels 
under reducing conditions and transferred to polyvinylidene difluoride membranes (Immo-
bilon-P; Millipore, Bedford, MA). Blots were probed with anti-dematin (BD Biosciences) 
or anti-eIF2 (Santa Cruz Biotechnology) antibodies. Second-step reagents were HRP-
conjugated goat anti-mouse IgG or goat anti-rabbit IgG from Dako (Glostrup, Denmark). 
Peroxidase activity was visualized by ECL using Western blotting detection reagents from 
Amersham Biosciences according to their instructions.
Cytospins, sections and staining
E12.5 embryonic blood cells were collected in PBS/1mM EDTA and cytocentrifuged. The 
preparations were stained with neutral benzidine and histological dyes as described.2 For the 
sections of embryonic blood cells, wild type and EKLF-/- E12.5 yolk sacs were immersion fixed 
in 3% paraformaldehyde/1% glutaraldehyde in Millonig’s buffer at 4°C overnight or longer. 
Then they were rinsed with Millonig’s buffer and post-fixed in 1% OsO
4
 at 4°C. The yolk sacs 
were dehydrated through an ascending acetone series and embedded in epon. Sections were cut 
at 1 µm and stained with toluidine/methylene blue. Images of the cytospins and sections were 
acquired with an Olympus BX40 microscope. The lens used was Olympus Plan 100X/1.25. The 
acquisition software used was Viewfinder Lite Version 1.0.125 and Studio Lite Version 1.0.124, 
(Pixera Corporation), and image processing was done in Adobe Photoshop Elements.
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Abstract
Three-dimensional organisation of a gene locus is important for its regulation, as re-
cently demonstrated for the β-globin locus. When actively expressed, the cis-regulato-
ry elements of the β-globin locus are in proximity in the nuclear space, forming a com-
partment termed the Active Chromatin Hub (ACH). However, it is unknown which 
proteins are involved in ACH formation. Here we show that EKLF, an erythroid 
transcription factor required for adult β-globin gene transcription, is also required 
for ACH formation. We conclude that transcription factors can play an essential role 
in the three-dimensional organisation of gene loci.
Introduction
The mouse β-globin locus contains multiple β-like globin genes, arranged from 5’ to 3’ in 
order of their developmental expression (Fig. 1a). The adult-type βmaj-gene is transcribed 
at a very low level during primitive erythropoiesis in the embryonic yolk sac, but becomes 
expressed at high levels around day 11 of gestation (E11) when definitive erythropoiesis 
commences in the fetal liver.29 The β-globin locus control region (LCR) is essential for ef-
ficient globin transcription.2,14 It consists of a series of DNaseI hypersensitive sites (HS) lo-
cated ~50 kb upstream of the βmaj promoter (Fig. 1a). We have shown that the β-globin locus 
forms an Active Chromatin Hub (ACH) in erythroid cells.28 The ACH is a nuclear compart-
ment dedicated to RNA polymerase II transcription, formed by the cis-regulatory elements 
of the β-globin locus with the intervening DNA looping out. The ACH consists of the HS 
of the LCR, two HS located ~60 kb upstream of the embryonic εy-globin gene (5’HS-62/-
60) and 3’HS1 downstream of the genes. In addition, the actively expressed globin genes 
are part of the ACH.4,28 In erythroid precursors which do not express the globin genes yet, a 
substructure of the ACH, called a chromatin hub (CH)23 is found, which excludes the genes 
and the HS at the 3’ site of the LCR.22
Expression of the βmaj-gene requires the presence of the erythroid Krüppel-like transcrip-
tion factor EKLF, the erythroid-specific member of the Sp/XKLF-family.19 EKLF-/- mice 
die of anaemia around E14, because of a deficit in β-globin expression.21,25 The β-globin 
locus contains a number of EKLF binding sites, in particular in the LCR and the βmaj-globin 
promoter.3,24 Because βmaj-globin expression depends on the presence of EKLF, we were 
interested in determining whether EKLF is involved in the formation of the ACH.
Results and discussion
We used chromatin conformation capture (3C) technology6 to investigate the three-dimen-
sional conformation of the mouse β-globin locus in the absence of EKLF. Cells from E12.5 
EKLF-/- and wild type fetal livers were crosslinked with formaldehyde, followed by restric-
tion enzyme digestion of the DNA. The samples were ligated under conditions that favour 
the ligation of DNA fragments that are physically connected through the crosslinks. Quan-
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titative PCR across the junctions is used to determine the relative crosslinking frequen-
cies between restriction fragments in the locus. This provides an indication of the nuclear 
proximity of DNA fragments in vivo.6,22,28 Crosslinking frequencies were determined for a 
total of 66 junctions that can be formed between 12 selected HindIII fragments spread over 
~170 kb of DNA encompassing the β-globin gene cluster (Fig. 1). Examples of quantitative 
PCR reactions with some of the primer combinations are shown in Fig. 1b. An overview 
of the locus-wide crosslinking frequencies of a restriction fragment that contains the βmaj 
promoter is shown in Fig. 1c. The brain serves as a non-expressing control tissue (light 
curve), in which the β-globin locus appears to adopt a linear conformation.28 In wild type 
E12.5 fetal liver cells, high crosslinking frequencies are found with the LCR and 5’HS-62, 
indicating their proximity to the βmaj promoter in vivo (black curve). In the absence of EKLF 
however, these crosslinking frequencies are much lower and no interaction with a distal site 
stands out clearly (grey curve), showing that the βmaj promoter does not participate stably in 
a spatial clustering of chromatin. A comparable pattern is observed with locus-wide crosslink-
ing frequencies of a fragment containing 5’HS2 (Fig. 1d). Together with 5’HS3, 5’HS2 is 
the most prominent transcriptional activating element of the LCR.8-10,12,15 Interactions with 
5’HS-62, βmaj, 3’HS1, and the other HS of the LCR are strongly reduced in the absence of 
EKLF, indicating that 5’HS2 requires the presence of EKLF to participate in the ACH. 
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Figure 1. EKLF influences the spatial organisation of the β-globin locus.
a Schematic presentation of the mouse β-globin locus. Globin genes are indicated by triangles. Olfactory recep-
tor genes (MOR5’b and MOR3’b) are indicated by rectangles and numbered. DNaseI HS are shown as black 
ovals with arrows. The scale is in kb. b Examples of PCR-amplified ligation products run on a 2% agarose gel. 
Primer combinations are shown on the right. XPB is used to standardise the amount of template.2 +/+ = wildtype; 
-/- = EKLF knockout. c-d Locus-wide relative crosslinking frequencies in E12.5 fetal livers. Results obtained with 
wild type livers are shown in black; EKLF-/- livers in grey, non-expressing brains in light. The x-axis shows posi-
tion in the locus. Grey shading indicates the positions and sizes of the HindIII fragments containing primers used 
in the PCR analysis. Black shading represents the position of the fragment containing the “fixed” primer in the 
HindIII fragment of the βmaj-gene (c) or 5’HS2 (d). Within each graph, the highest crosslinking frequency value is 
set to 1. Error bars indicate the standard-error-of-mean.
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The results shown in Fig. 1 demonstrate that the complete ACH is not formed in the absence 
of EKLF. However, the observed crosslinking frequencies in EKLF-/- fetal liver cells are 
still higher than those found in non-expressing brain cells indicating a different, non-linear, 
structure. To investigate this, we compared the locus-wide crosslinking frequencies of re-
striction fragments containing 5’HS-62 and 5’HS4/5 (Fig. 2). These sites participate in the 
CH present in erythroid progenitor cells before the globin genes are transcribed.22 Examples 
of quantitative PCR reactions with some of the primer combinations are shown in Fig. 2a. 
The graphs in Fig. 2b show that in wild type fetal liver cells, 5’HS-62 is in proximity to the 
LCR, βmaj and 3’HS1. In EKLF-/- fetal liver cells, 5’HS-62 interactions with the HS at the 
5’ side of the LCR and with the distal 3’HS1 still stand out, whereas all other crosslinking 
frequencies are strongly reduced. This indicates the presence of a globin CH, containing 
5’HS-62/-60, the HS at the 5’ side of the LCR, and 3’HS1. The same structure is apparent 
when analysing locus-wide crosslinking frequencies of a restriction fragment containing 
5’HS4/5 at the 5’ side of the LCR (Fig. 2c).
There are remarkable similarities between the structure of the β-globin locus in EKLF-/- fe-
tal liver cells and that observed in I/11 erythroid progenitor cells which do not yet express 
globin22 (Supplementary Fig. 1). This suggests that EKLF is required for progression from 
the chromatin hub present in erythroid precursors to a fully active ACH. To investigate if 
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Figure 2. An ACH substructure is formed 
independent of EKLF.
a Examples of PCR-amplified ligation products 
run on a 2% agarose gel. Primer combinations 
are shown on the right. b, c Locus-wide relative 
cross-linking frequencies of HindIII restriction 
fragments containing 5’HS-62 (b), and 5’HS4/5 
(c). See legend to Fig. 1 for other details.
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this β-globin structure in EKLF null cells is a direct consequence of EKLF-deficiency or 
caused by a general differentiation failure, we analysed expression of the erythroid-specific, 
but EKLF-independent, α-globin gene locus. Consistent with previous observations, prima-
ry transcript in situ hybridisation experiments show that α-globin expressing cells are abun-
dantly present in the EKLF-/- fetal liver, demonstrating that in the absence of EKLF cells 
are progressing to the stage of active globin expression (Fig. 3a).17,21,25,32 We do observe that 
EKLF-/- fetal livers contain approximately 20% less α-globin expressing cells than wild 
type fetal livers (~55% versus 70% of the total number of cells in the fetal liver). Whereas 
this may explain the small reduction in crosslinking frequencies observed between some of 
the β-globin elements, it cannot account for the strongly reduced locus-wide crosslinking 
frequencies seen with, for example, βmaj and 5’HS2 (Fig. 1c,d). We conclude that the dra-
matically altered chromatin organisation of the β-globin locus in EKLF null erythroid cells 
is not due to a general differentiation problem. 
To substantiate the specificity of the changes in the three-dimensional structure of the β-
globin locus in the absence of EKLF we investigated interactions between the promoter and 
remote regulatory element of the erythroid-specific, EKLF-independent, α-globin locus. 
The mouse α-globin locus has two active genes in the fetal liver, α1 and α2, and contains a 
HS 26 kb upstream of the α-globin promoter that is similar to the human α-globin enhancer 
HS-40 (Fig. 3b).11 It is likely that, analogous to the LCR, this element will interact with the 
α-like globin promoters to enhance expression. The crosslinking frequencies of the restric-
tion fragments containing HS-26 and α2-globin are shown in Fig. 3c, d. In wild type and 
EKLF-/- fetal liver cells, the crosslinking frequencies are clearly higher than those observed 
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Figure 3. HS-26-promoter interactions in the 
α-globin locus are not affected by EKLF.
a In situ hybridisation of E12.5 fetal liver cells of 
wildtype and EKLF-/- fetuses, detecting α-globin 
mRNA (red) and primary transcripts (green). DAPI 
staining (blue) is used to show nuclear DNA. White 
arrows indicate cells that were scored negative for 
α-globin expression. b Schematic drawing of the 
mouse α-globin locus. The black oval with arrow 
depicts the position of the HS-26 distal regulatory 
element. The α-like globin genes are indicated by 
grey triangles. Small arrows = HindIII restriction 
sites. c Example of PCR-amplified ligation prod-
ucts of HindIII restriction fragments containing 
HS-26 and α2 in E12.5 day fetal liver and brain 
cells of wildtype and EKLF-/- fetuses. The XPB 
PCR product is used as template control. d Quanti-
fied data of PCR-amplified ligation products. Dark 
bars = fetal liver; light bar = brain. Error bars 
indicate standard-error-of-mean. The crosslinking 
frequency in wildtype fetal liver cells is set to 1.
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in non-expressing brain tissue, indicating that HS-26 and the α2-globin gene are in close 
proximity in both types of erythroid cells. The slightly reduced interaction frequencies ob-
served in EKLF knockout compared to wild-type fetal liver can be explained by the 20% 
reduction of α-globin expressing cells (see above). We conclude that major alterations in 
spatial organisation are restricted to the EKLF-dependent β-globin locus. 
To further investigate if changes in the spatial organisation of the β-globin locus are a direct 
effect of the activity of EKLF, we wished to induce EKLF activation and simultanously 
prevent it from activating secondary pathways. For this, we used a fusion between EKLF 
and a modified estrogen receptor ligand binding domain (EKLF-lbd protein), that can be 
activated by 4-hydroxy-tamoxifen (4-OHT).18 We wanted to test whether, in an EKLF 
null background, activated EKLF-lbd protein restores ACH formation in the presence of 
the protein synthesis inhibitor cycloheximide (CHX). In such a set up, genes activated by 
EKLF cannot be translated into protein, and therefore any structural changes would have 
to be attributed to EKLF acting directly on the β-globin locus. Transgenic mice carrying an 
expression construct of an EKLF-lbd fusion protein were generated. To ensure expression 
of the fusion protein in EKLF null erythroid cells, we used the erythroid-specific pEV3 
expression vector20 and replaced the β-globin promoter by the α-globin promoter. West-
ern blot analysis demonstrates the presence of the HA-tagged EKLF-lbd fusion protein 
(Fig. 4a). We have previously shown that an EKLF-pEV3 transgene rescues the EKLF 
null mutation.27 To test if uninduced EKLF-lbd fusion protein is inactive, we crossed the 
EKLF-lbd transgenics with the EKLF knockout mice. No EKLF null::EKLF-lbd transgene 
pups were born. When we dissected the fetuses resulting from this cross at E12.5, we found 
that the EKLF null::EKLF-lbd transgenic fetuses were indistinguishable from EKLF null 
fetuses, e.g. displaying signs of severe anemia and having very pale fetal livers (data not 
shown). We conclude that the EKLF-lbd fusion protein is inactive and does not rescue the 
EKLF null mutation. 
To test the ability of activated EKLF-lbd fusion protein to rescue β-globin gene transcrip-
tion, we cultured EKLF null::EKLF-lbd fetal liver cells in the presence of 4-OHT (Fig. 4b). 
After 16 hours of culturing, a subset of the cells was used to check for the activation of 
β-globin gene expression. Real-time RT-PCR analysis of steady-state mRNA levels shows 
that the β-globin gene is activated in EKLF null::EKLF-lbd cells in the presence of 4-OHT 
(Fig. 4c). The amount of β-globin transcripts in the tamoxifen-rescued cells is much lower 
than in wild type cells, which is is not surprising since the former cells just start to accumu-
late β-globin mRNA levels. We conclude that the EKLF-lbd fusion protein can be induced 
with 4-OHT to activate β-globin gene expression. Moreover, β-globin gene activation by 
4-OHT-induced EKLF-lbd also occurs in the presence of CHX (Fig. 4c). 
The remaining cells were subjected to 3C analysis using a procedure modified for use with 
small numbers of cells. Since the amount of material was limiting, we focussed on the 
analysis of interactions between 5’HS2, one of the most prominent activating elements of 
the LCR, and the promoter of the βmaj gene.4,28 In untreated EKLF null fetal liver cells, we 
found similarly low crosslinking frequencies between 5’HS2 and βmaj regardless of the pres-
ence of the (uninduced) EKLF-lbd protein (Fig. 4d). In contrast, this interaction is restored 
in EKLF null::EKLF-lbd cells after culturing for 16 hours in the presence of 4-OHT. Impor-
tantly, the same effect is also observed when CHX and 4-OHT are present simultaneously 
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(Fig. 4d). These data indicate that ACH interactions are restored in EKLF null::EKLF-lbd 
cells when the EKLF-lbd fusion protein is activated by 4-OHT. Since this also occurs when 
protein synthesis is inhibited through the addition of CHX, we conclude that EKLF is di-
rectly involved in the completion of ACH formation.
In conclusion, our data show that a chromatin hub is formed independent of EKLF during 
erythropoiesis, consisting of the 5’HS-62/-60, the HS at the 5’ side of the LCR, and 3’HS1. 
EKLF is required for the progression to, or stabilisation of, a fully functional ACH, which 
includes the remaining HS of the LCR and the actively transcribed βmaj globin gene (Fig. 5). 
The βmin gene which is also expressed in definitive erythroid cells is known to alternate with 
the βmaj gene in the ACH in a dynamic “flip-flop” mechanism.29,33 The EKLF-independ-
ent chromatin hub is structurally similar to that present in erythroid precursor cells, which 
were previously found to already contain EKLF mRNA7 and protein (data not shown). This 
suggests that modifications of the EKLF protein or other protein factors are required to col-
laborate with EKLF in organizing a fully active β-globin ACH.  
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Figure 4. EKLF is directly involved in the spatial organisation of the β-globin locus.
a Schematic drawing of the EKLF-lbd expression construct used to generate transgenic mice. The 
Western blot shows expression of the EKLF-lbd fusion protein in the fetal livers of transgenic 
mice detected by an antibody recognizing the HA tag. b Flow chart of the experimental design. 
Fetal livers are isolated from E12.5 control- and EKLF null::EKLF-lbd tg fetuses, disrupted and 
the erythroid cells are cultured in the presence of 4-OHT with or without CHX for 16 hours. 
Cells are then harvested, crosslinked with formaldehyde and subjected to 3C analysis. From a 
portion of the cells, RNA is isolated to check β-globin gene expression. c Expression of β-globin 
analysed by real-time RT-PCR. Expression of Hprt was used to standardize the β-globin expres-
sion levels. Representative experiment is shown. d 3C analysis of the interactions between 5’HS2 
and the β-globin promoter. Representative examples of the PCR reactions are shown. Error bars 
indicate the standard-error-of-mean. Calreticulin was used as template control.
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Recent work has shown that deletion of the promoter of the adult β-globin gene in the 
human β-globin locus mildly affects ACH formation, suggesting that in addition to the 
β-globin promoter other cis-regulatory elements in the human β-globin locus are involved 
in these interactions.23 EKLF binding sites are also present in the LCR, in particular in 
5’HS3, and in the 3’ enhancer of the β-globin gene.13,31 Together these data suggest that the 
EKLF-dependent interactions of the adult β-globin genes with the ACH involve multiple 
cis-regulatory elements. 
 It is also interesting to note that in the EKLF knockout absence of spatial interactions coin-
cides with loss of chromatin accessibility at 5’HS3 and the βmaj-promoter.5,32 We conclude 
that EKLF is necessary for hypersensitive site formation and the participation of the LCR 
and the β-globin promoter in the ACH, probably through interactions with a SWI/SNF-re-
lated chromatin remodelling complex.1 Thus, EKLF is the first example of a transcription 
factor that is required for the proper spatial organisation of a mammalian gene locus.
Figure 5. The formation of the complete ACH requires the presence of EKLF.
A two-dimensional representation of the proposed three-dimensional structure of the ACH 
is shown. The ACH is a nuclear compartment dedicated to RNA polymerase II transcription, 
formed by cis-regulatory elements of the β-globin locus.22 In erythroid cells, a substructure of 
the ACH, consisting of 5’HS-62/-60, 3’HS1 and HS at the 5’ side of the LCR, is formed inde-
pendently of EKLF. Progression of this substructure to a fully functional ACH, including the HS 
at the 3’ side of the LCR and the active β-globin gene, is dependent on the presence of EKLF. 
Grey sphere on the left: ACH substructure. Grey sphere on the right: ACH. RNA transcripts are 
indicated as black lines. See legend to Fig. 1a for other details.
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Materials and methods
Chromosome Conformation Capture
EKLF+/- mice21 were crossed and E12.5 fetal livers and brains were isolated. 3C analysis was 
performed as described,26 with minor adjustments. Individual liver and brain samples were sub-
jected to formaldehyde crosslinking. HindIII restriction enzyme digestion of crosslinked DNA, 
intra-molecular ligation, reversal of crosslinks, PCR analysis of ligation products and calculation 
of relative crosslinking frequencies was done with 15 pooled wildtype fetal livers, 15 EKLF-/- 
fetal livers and cells of 3 pooled EKLF-/- brains. Two independent samples were prepared for the 
analysis. Each PCR reaction was performed in duplicate and repeated at least 3 times.
α-globin
HS-26 - α2 promoter crosslinking frequencies were determined with the DNA samples de-
scribed above and primers recognising the HindIII restriction fragment containing HS-26 (5’-
GAATCTCCATCTCCAAGGG-3’) and the α2 promoter (5’-AAGAGGTGCAGGTGTAT-
TACTG-3’). In situ hybridisation of E12.5 fetal liver cells was performed as described before.30 
Cells were scored positive if α-globin mRNA, primary transcript, or both, was detected. >300 
cells were counted to determine the percentage of α-globin-positive cells in each sample.
Generation of EKLF-lbd transgenic mice
A DNA fragment containing EKLF cDNA and the first intron was linked in frame with the 
HA tag sequence at the 5’ side and the lbd coding sequence at the 3’ side. This construct 
was cloned into the pEV3 vector20 and the β-promoter was replaced by a fragment 
containing the α-globin promoter. The vector was linearised by AatII and transgenic mice 
were generated as described.16
Culture of primary fetal liver cells
Livers were isolated from E12.5 control- and EKLF null::EKLF-lbd tg fetuses. The geno-
type of the fetuses was confirmed by PCR. Single cell suspensions of individual fetal livers 
were cultured for 16h in StemPro-34TM containing 1% BSA, 1% glutamine and 10 units/ml 
EPO, but without serum supplement. The EKLF-lbd was activated by supplementing the 
medium with either 250nM 4-hydroxy-tamoxifen (4-OHT) alone or with 250nM 4-OHT 
and 20 µg/ml cycloheximide (CHX). After 16h of culture, cells were harvested and a small 
aliquot was taken for RNA isolation. The 16h period was chosen because it allowed detec-
tion of 4-OHT-induced β-globin gene transcription without CHX causing toxic effects. 
Fixation of the remainder of the cells with formaldehyde and subsequent isolation of nuclei 
was performed as described before.28
Preparation of cDNA and Real-time PCR
RNA was isolated using Trizol, according to the manufacturers guidelines (Invitrogen). 
The Super-scriptTM reverse transcriptase Kit (Invitrogen) was used for preparation of 
oligo-dT primed cDNA. Expression levels were determined on the Bio-Rad I-Cycler us-
ing the qPCRTM Core kit for Sybr Green 1 (Eurogentec). Expression levels of Hprt were 
used for normalization of β-globin expression levels. Primers used were as follows: Hprt-s, 
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AGCCTAAGATGAGCGCAAGT; Hprt-as, ATGGCCACAGGACTAGAACA; β-major-
s, ATGCCAAAGTGAAGGCCCAT; β-major-as, CCCAGCACAATCACGATCAT.
Preparation of 3C templates
For the limiting number of cells (approximately 1.106) obtained from the individual EKLF 
null::EKLF-lbd tg fetal livers, we adapted the previously described protocol.28 Cross-linked 
nuclei of E12.5 fetal livers were re-suspended in 50 µl digestion buffer containing 0.1% SDS 
and incubated for 1 hour at 370C with agitation, Triton X-100 was added to 2.6% and the nuclei 
were further incubated for 1 hour at 370C. The cross-linked chromatin was digested overnight at 
370C with 10 units of HindIII. The restriction enzyme was heat-inactivated (25 minutes at 650C). 
After addition of 200 µl of 1.25x ligase buffer and 40 U of T4 ligase the chromatin was ligated 
for 4.5 hours at 160C followed by 30 minutes at room temperature. Proteinase K was added and 
samples were incubated overnight at 650C to reverse the cross-links. The following day samples 
were incubated for 30 minutes with RNAse and the DNA was purified by phenol extraction and 
ethanol precipitation using glycogen as a carrier. Locus wide cross-linking frequencies of wild 
type fetal livers treated with this adapted protocol were similar as those found previously (data 
not shown). PCR analysis of the ligation products was performed as described before.22,28
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Supplementary Figure 1. The spatial organisation of the β-globin locus in EKLF-/- fetal liver cells is similar 
to that observed in erythroid progenitor cells.
(a, b, c, d) Comparison of locus-wide crosslinking frequencies of the HindIII restriction fragment containing 
5’HS-62 (a), 5’HS4/5 (b), 5’HS2 (c), and βmaj (d), in fetal livers (graphs on the left) and I/11 erythroid progenitor 
cells (graphs on the right). Grey curves in graphs on the right: proliferating I/11 erythroid progenitor cells, not 
expressing globins. Black curves in graphs on the right: I/11 cells after induction of globin expression. Other 
details are as for Fig.1.
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EKLF and globin
The initial discovery of the LCR of the β-globin locus15 has led to an intense research ef-
fort to elaborate how this region is important for proper regulation of the genes within the 
β-globin locus. The LCR is required for position-independent and copy number-dependent 
high-level β-globin gene transcription. The mouse LCR consists of 6 HS. Deletion of any 
one of HS 1 to 4 leads to decreased globin expression, suggesting that the HS co-operate 
in a holo-complex.4,12,18 LCRs are cis-acting elements that are located far away from the 
promoters they control. The mouse β-globin LCR is located approximately 50 kb upstream 
from the βmaj promoter. A number of models have been proposed to explain long-distance 
transcriptional control by the LCR; the accessibility-, the scanning- and the looping model. 
The looping model best explains a number of properties of the β-globin LCR. In studies 
in which a marked β-gene was placed at various positions in the human β-globin locus, it 
was demonstrated that the genes compete for activation by the LCR. The gene closest to 
the LCR has the highest level of expression.10 Further to this it was demonstrated that the 
globin genes are not simultaneously actively transcribed, suggesting competition for direct 
contact with the LCR.14,37 However, it was not until the application of two techniques, Chro-
mosome Conformation Capture30 and RNA-TRAP,6 that it was demonstrated that the LCR 
is physically in close proximity to the actively transcribed gene. In fact, other more distally 
located HS, 5’HS-60/-62 and 3’HS1, also cluster to the LCR and the actively transcribed 
gene, to form a spatial organisation of the globin locus that is called the Active Chromatin 
Hub (ACH). Further studies showed that a substructure of the ACH is present in erythroid 
progenitors, consisting of the 5’HS-60/-62, the 3’HS1 and the 5’ site of the LCR. Later in 
erythroid differentiation, when the globin genes are transcribed, the 3’ site of the LCR and 
the globin gene co-localise with this substructure to form the ACH. 
To further study the ACH, it is of interest to identify the proteins involved in its formation. 
A logical first choice of protein to study was EKLF. This transcription factor is required 
for the expression of adult β-globin genes. In the absence of EKLF, mice die of anemia 
around E14 due to a deficit in β-globin expression.21,25 Furthermore, the β-globin locus 
contains several functional EKLF binding sites. The best studied is the one in the βmaj 
promoter. Some mutations in this binding site lead to β-thalassemia. Other EKLF binding 
sites are found in the LCR. With the 3C technique we demonstrated that EKLF is necessary 
for proper ACH formation (Chapter 4). An ACH substructure, reminiscent of that found 
in erythroid progenitors, was observed in E12.5 EKLF-/- fetal livers. The formation of this 
substructure is apparently independent of EKLF. However, the completion of the ACH is 
EKLF-dependent. 
With the 3C technique we clearly demonstrated that EKLF is involved in the organisation 
of the proper spatial organisation of the β-globin locus for active transcription of the adult 
globin genes. However, the dynamics of the completion of the ACH remains enigmatic. 
A tracking model was proposed to describe the interactions of the HNF-4α promoter and 
its enhancer.16 HNF-4α codes for a hepatic specific transcription factor27 and its expres-
sion is controlled by an enhancer, 6.5kb upstream of the transcription start site. Before the 
gene is transcribed, proteins (such as histone acetyltransferases and chromatin remodelling 
proteins) are bound to the enhancer. During differentiation the enhancer/protein complex 
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moves along the intervening DNA towards the promoter, where upon arrival transcription 
starts.16 Using R10 or I/11 erythroid progenitor cells it might be possible to show that the 
β-globin promoter is recruited to the LCR in a similar way. Particular proteins might be 
detected at the LCR before active transcription, but at the promoter only when genes are 
actively expressed. However, important for the demonstration of the tracking model is the 
binding of the enhancer/protein complex to the intervening DNA. In the Caco-cells used 
to demonstrate the tracking mechanism, the protein/enhancer complex is brought to the 
promoter over a period of days. It is not known how long this phenomenon takes for the 
β-globin locus. It is known that alternate transcription of the β- and γ-globin genes takes 
place within minutes.14 The state of the ACH in between transcription of either of the globin 
genes may not be completely similar to the ACH substructure found in progenitor cells and 
in EKLF null cells. Nevertheless, it does indicate that recruitment of the promoter to the 
LCR takes place within minutes, which would complicate the demonstration of the binding 
of the enhancer/protein complex to the intervening DNA.
However, the finding that the distance between two genes influences the competitive ad-
vantage of the gene closest to the LCR10 still conflicts with a tracking mechanism for the 
β-globin locus. Therefore, it is more likely that the gene promoter contacts the LCR in a 
stochastic manner. This is facilitated by the formation of the substructure of the ACH. Then, 
the full ACH is stabilised by the combination of DNA binding sites and protein complexes. 
Formation of the ACH results in a local increase of binding sites for transcription factors 
that is postulated to result in an increase of its cognate factors and associated chromatin 
modifiers, which enhances transcription.9 The active organisation of the locus would use 
similar principles (but on a larger scale) as the folding of an enzyme to create an active 
site or “pocket”.23 The EKLF-dependent completion of the ACH leads to a stable complex, 
necessary for high-level transcription. However, the formation of this complex is reversible. 
This is demonstrated by a low expression of βmin, whose promoter competes for activation 
by the LCR with the βmaj promoter, leading to alternate expression of both genes in a flip-
flop mechanism.31
For further study of the dynamics of the ACH formation, a cell line such as the one de-
scribed in Chapter 2 will be very useful. In particular, an EKLF null cell line that carries a 
tamoxifen-inducible EKLF and the human globin locus would be advantageous. Although 
it has been shown that EKLF is necessary for establishment of hypersensitivity of 5’HS2 
and 5’HS3 and the β-globin promoter, and for the completion of the ACH, the dynamics 
still have to be uncovered. For instance, HS could be formed immediately upon activation 
of an inducible EKLF by tamoxifen or cells may have to go through a cell division before 
HS are formed.
In analogy with the mouse β-globin ACH, the completion of the human β-globin locus 
ACH is presumably EKLF-dependent. After deletion of the β-globin promoter from the 
human β-globin locus, the gene is no longer transcribed. However, crosslinking frequen-
cies between the β-globin gene and other HS are only ~30% decreased.23 This indicates 
that the formation of the ACH is not a direct effect of transcription. However, since 
EKLF is important for the completion of the ACH, one could predict that deletion of the 
β-globin promoter, that contains a functional EKLF binding site, would lead to a simi-
lar incomplete ACH that is found in EKLF null mice. The difference between the ACH 
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structure found in absence of EKLF and in absensence of the β-globin promoter may be 
explained by a stabilisation of the ACH of the human locus by other sites, in particular 
two 3’ enhancers located in the third exon and downstream of the human β-globin gene.1 
This stabilisation may be EKLF dependent since the 3’ enhancer contains potential EKLF 
binding sites.35
The finding that EKLF plays an important role in the establishment of the ACH provides the 
basis for future work in the involvement of other factors in ACH formation. Transcription 
factors of interest are GATA1 and NF-E2, as it has been shown that these factors play a role 
in β-globin expression.19,32,36 Another protein that is likely to play a role in ACH formation 
is CTCF, as this factor binds some of the HS that are clustered in the substructure of the 
ACH.5
In the work described in Chapter 4 we studied the participation of DNA fragments located 
on a stretch of ~130kb from 5’HS-62 to 3’HS1 in the ACH. However, the ACH may consist 
of more sequences. In fact, we have already demonstrated that 5’HS-80, further upstream 
of the locus, participates in the ACH (W. de Laat, pers. com.). Since we view the ACH 
as a nuclear compartment, dedicated to RNA polymerase II activity, it is not unlikely that 
other genes cluster to the ACH as well. Interestingly, some EKLF target genes described in 
Chapter 3 (AHSP and KCNN4) are located on the same chromosome as the β-globin locus. 
Further studies using 3C, in situ hybridisation or DNA-TRAP methods, could demonstrate 
whether these genes are in close proximity to the β-globin ACH when actively transcribed.
EKLF and other targets
The finding that the EKLF null-phenotype cannot be rescued by exogenous expression of 
human γ-globin24 indicated that EKLF regulates expression of other genes important for 
definitive erythropoiesis, in addition to the β-globin gene. We have searched for additional 
target genes by micro-array screening. The way we performed the micro-array screenings 
can be considered as a fishing expedition; a relatively quick way of searching for differen-
tially expressed genes, of which the significance has to be established. The micro-array data 
might have yielded more results if the experiments had been performed repeatedly and if 
dye-swaps could have been included. We were limited by the amount of RNA needed for 
probe production and the number of micro-arrray chips available. Nowadays protocols have 
been optimised for reliable RNA amplification, which allows for efficient probe production 
and screening multiple micro-arrays. This may not be necessary for RNA isolated from 
cultured cells, but for E12.5 fetal livers this is very useful. Furthermore, the micro-array 
chips we have used represent fewer genes than initially thought. The 9k erythroid-enriched 
chip was used because it was thought to represent many erythroid specific genes. However, 
half of the spots consist of T-cell enriched cDNAs. The other half consists of cDNAs that 
are enriched for genes expressed in the I/11 pro-erythroblast cell line. As a result, highly 
expressed genes are represented multiple times on the chip. To some extent this is an advan-
tage, since data from multiple spots for a particular gene provide a valuable internal control. 
However, some genes are over-represented, as representation of a gene on the chip depends 
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on its expression level. Therefore, genes that are expressed at a low level are most likely not 
represented on the chip. The many spots (more than 1000) representing βmaj hamper the 
normalisation of the data, since this gene is differentially expressed in EKLF-/- compared to 
wild type cells. Nowadays chips, with more global gene representation, are available and 
thus, should provide an opportunity to identify additional target genes to the ones described 
in this thesis. 
Despite all these drawbacks, we successfully discovered new target genes. Chapter 3 con-
tains a list of genes that appear to be regulated by EKLF. We have focussed on genes that are 
activated by EKLF. However, it has been proposed that EKLF can also act as a repressor.7 
Our list of genes also includes genes that may be repressed by EKLF, since they are higher 
expressed in absence of EKLF compared to wild type. The differential expression of some 
of the listed genes was verified by real time PCR (AHSP, heme synthesis genes, KCNN4 
(data not shown)), Northern blot (AHSP and ALAS2) or Western blot (Epb4.9) analysis. 
More direct evidence for the involvement of EKLF in regulating these genes would be the 
demonstration that EKLF binds to the promoter of these genes in vivo. The establishment 
of a transgenic mouse line, carrying a gene coding for a fusion protein of EKLF and a 23aa 
tag that can be biotinylated,8 makes this experiment feasible. It has been demonstrated that 
a similarly tagged GATA-1 gene can be successfully immuno-precipitated from chromatin 
of erythroid cells (E. Katsantoni, pers. com.). In parallel, newly developed single chain 
llama antibodies directed against EKLF (H. Braun, unpublished data) can be used for simi-
lar chromatin immuno-precipitation (ChIP) experiments. These single chain antibodies are 
expected to have high affinity for their antigen.34
Since EKLF is an erythroid-specific transcription factor, it is not surprising that most of the 
(potential) target genes are either erythroid-specific or highly expressed in erythroid cells. 
Most of these genes have a similar expression pattern as the βmaj gene, i.e. they become 
highly expressed late in the differentiation program. This is in agreement with the observa-
tion that EKLF appears to have no function until the pro-erythroblast stage of definitive 
cells. In embryonic blood cells, lack of expression of two of these target genes leads to the 
appearance of Heinz bodies and an unstable membrane. Another gene that may be regulated 
by EKLF, KCNN4, may explain another aspect of the phenotype. This gene codes for the 
Gardos channel;13 a Ca2+-activated K+ channel. It is expressed in multiple tissues, including 
erythroid cells, in which it is strongly upregulated late in differentiation.17 It has been shown 
that this channel plays an important role in adaptation to changes in osmotic pressure.33 In 
erythroid cells, KCNN4 plays an important role in cell size decrease, by excretion of KCl 
and water.17 Interestingly, we found that during differentiation of primary pro-erythroblasts 
the size of EKLF null cells does not decrease as much as wild type cells (Chapter 2 and 
3). Lack of upregulation of KCNN4 may explain this phenotype. Using the culture method 
described in Chapter 2, the effect of absence of EKLF and hence lack of high expression of 
KCNN4 on osmotic pressure adaptation could be studied.
The availability of EKLF null cells from a transgenic line containing a tamoxifen-inducible 
EKLF gene, allows gene expression studies in the absence or presence of active EKLF. In 
fact, we have performed such an experiment with primary transgenic cells. EKLF null cells 
carrying a tamoxifen inducible EKLF were isolated from E12.5 fetal livers and expanded in 
culture for 10 days before induction of terminal differentiation. 24 Hours before this induc-
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tion of terminal differentiation, tamoxifen was added to half of the culture and the effect of 
the activated EKLF was studied by gene expression with micro-arrays 12 hours after induc-
tion. The 12 hours after induction is quite short to detect an effect of the activated EKLF as 
judged by the 2log values in Table I, Chapter 3; The table shows that potential EKLF target 
genes are not extensively differentially expressed in wild type and EKLF KO cells after 12 
hours of induction. However, the data suggested that the activated EKLF rescued the gene 
expression of EKLF target genes to some extent (data not shown). Thus, the tamoxifen-in-
ducible EKLF is a useful tool to demonstrate EKLF dependent expression of genes. 
EKLF in action
Although there had been indications that EKLF is not only present28 but also active in em-
bryonic cells (low expression of βmaj is EKLF-dependent31 and a reporter gene revealed 
EKLF activity in embryonic cells29), in Chapter 3 we show for the first time that endog-
enous EKLF target genes (AHSP and Epb4.9) are dependent for their high expression on 
the presence of EKLF in embryonic cells. This raises the question whether other EKLF 
target genes are expressed in embryonic blood cells. In addition, our results suggest that the 
mere presence of EKLF is not sufficient for transcription of its target genes. This can be 
demonstrated in primitive cells (AHSP is expressed but βmaj is not), as well as in definitive 
cells. EKLF appears to be present at the pro-erythroblast stage in definitive cells, judged by 
the presence of RNA in proliferating I/11 cells11 and by protein in primary pro-erythroblasts 
(Western blot, data not shown). However, at this stage the target genes are not expressed. 
Interestingly, the completion of the ACH and the expression of EKLF target genes in defini-
tive cells appear to take place more or less simultaneously. 
Another indication that the mere presence of EKLF does not necessarily lead to expression 
of its target gene comes from a study by Luo et al.20 While it was previously thought that 
EKLF is only expressed in the erythroid cell lineage, Luo and colleagues demonstrated that 
EKLF is expressed in macrophages and regulates the expression of interleukin (IL)-12 p40. 
Depending on the activation status of the macrophages, EKLF activates or represses this 
gene. This is the first time that EKLF activity is demonstrated in non-erythroid cells and the 
first endogenous gene that can be repressed by EKLF. 
The activity of EKLF can be regulated at several different levels. These include 1) the 
amount of protein present in the nucleus, 2) posttranslational modifications and 3) the co-
operation with other proteins. It is unclear that EKLF is regulated at the first level, as pre-
liminary data from the Western blot (data not shown) suggest that EKLF is not upregulated 
after the pro-erythroblast stage of differentiation.
However, a number of articles report posttranslational modifications of EKLF (phospho-
rylation22 and acetylation38,39) and its significance for its activation capacity. For further 
study of post-translational modifications, the construct coding for a bio-tagged EKLF pro-
tein can be helpful. The fusion protein could be isolated from mice carrying this construct 
from various cells, such as embryonic cells, pro-erythroblasts and differentiating cells (us-
ing the culture technique described in Chapter 2). Analysis of the purified protein by mass 
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spectrometry may reveal differences in modifications in various cells at various differentia-
tion stages. Alternatively, the llama antibodies could be used, although the affinity of these 
antibodies for EKLF may be weaker than the high affinity of avidin/streptavidin for bioti-
nylated EKLF. However, it has the advantage that only endogenous EKLF will be purified. 
The importance of post-translational modification of EKLF could be further studied in the 
earlier described EKLF-/- cell line (Chapter 2). These pro-erythroblasts can be transfected 
with constructs that code for EKLF with mutations at post-translational modification sites. 
These mutations could effect target gene expression and demonstrate the importance of 
particular post-translational modification. 
The bio-tagged EKLF protein will also be useful in identifying EKLF partners, similar to 
the work performed with GATA-1 complexes.26 While in vitro studies have demonstrated 
EKLF co-operates with other proteins to regulate gene expression.2,7,38 the bio-tagged EKLF 
allows identification and characterization of such proteins in vivo. An interesting question 
is whether different EKLF containing complexes are formed at various stages of cellular 
differentiation (i.e. induced versus non-induced MEL cells or I/11 cells). More information 
with regard to EKLF partners may broaden the understanding of EKLF target gene regula-
tion and ACH formation.
References
1. Antoniou M, deBoer E, Habets G and Grosveld F (1988) The human beta-globin gene contains multiple 
regulatory regions: identification of one promoter and two downstream enhancers. Embo J 7:377-84
2. Armstrong JA, Bieker JJ and Emerson BM (1998) A SWI/SNF-related chromatin remodeling complex, E-
RC1, is required for tissue-specific transcriptional regulation by EKLF in vitro. Cell 95:93-104
3. Bakker WJ, Blazquez-Domingo M, Kolbus A, Besooyen J, Steinlein P, Beug H, Coffer PJ, Lowenberg B, 
Von Lindern M and Van Dijk TB (2004) FoxO3a regulates erythroid differentiation and induces BTG1, an 
activator of protein arginine methyl transferase 1. J Cell Biol 164:175-84
4. Bender MA, Roach JN, Halow J, Close J, Alami R, Bouhassira EE, Groudine M and Fiering SN (2001) 
Targeted deletion of 5’HS1 and 5’HS4 of the beta-globin locus control region reveals additive activity of the 
DNaseI hypersensitive sites. Blood 98:2022-7
5. Bulger M, Schubeler D, Bender MA, Hamilton J, Farrell CM, Hardison RC and Groudine M (2003) A com-
plex chromatin landscape revealed by patterns of nuclease sensitivity and histone modification within the 
mouse beta-globin locus. Mol Cell Biol 23:5234-44
6. Carter D, Chakalova L, Osborne CS, Dai YF and Fraser P (2002) Long-range chromatin regulatory interac-
tions in vivo. Nat Genet 32:623-6
7. Chen X and Bieker JJ (2001) Unanticipated repression function linked to erythroid Kruppel-like factor. Mol 
Cell Biol 21:3118-25
8. de Boer E, Rodriguez P, Bonte E, Krijgsveld J, Katsantoni E, Heck A, Grosveld F and Strouboulis J (2003) 
Efficient biotinylation and single-step purification of tagged transcription factors in mammalian cells and 
transgenic mice. Proc Natl Acad Sci U S A 100:7480-5
9. de Laat W and Grosveld F (2003) Spatial organization of gene expression: the active chromatin hub. Chro-
mosome Res 11:447-59
10. Dillon N, Trimborn T, Strouboulis J, Fraser P and Grosveld F (1997) The effect of distance on long-range 
chromatin interactions. Mol Cell 1:131-9
Discussion
95
11. Dolznig H, Boulme F, Stangl K, Deiner EM, Mikulits W, Beug H and Mullner EW (2001) Establishment of 
normal, terminally differentiating mouse erythroid progenitors: molecular characterization by cDNA arrays. 
Faseb J 15:1442-4
12. Fiering S, Epner E, Robinson K, Zhuang Y, Telling A, Hu M, Martin DI, Enver T, Ley TJ and Groudine M 
(1995) Targeted deletion of 5’HS2 of the murine beta-globin LCR reveals that it is not essential for proper 
regulation of the beta-globin locus. Genes Dev 9:2203-13
13. Gardos G (1958) The function of calcium in the potassium permeability of human erythrocytes. Biochim 
Biophys Acta 30:653-4
14. Gribnau J, de Boer E, Trimborn T, Wijgerde M, Milot E, Grosveld F and Fraser P (1998) Chromatin interac-
tion mechanism of transcriptional control in vivo. Embo J 17:6020-7
15. Grosveld F, van Assendelft GB, Greaves DR and Kollias G (1987) Position-independent, high-level expres-
sion of the human beta-globin gene in transgenic mice. Cell 51:975-85
16. Hatzis P and Talianidis I (2002) Dynamics of enhancer-promoter communication during differentiation-
induced gene activation. Mol Cell 10:1467-77
17. Hoffman JF, Joiner W, Nehrke K, Potapova O, Foye K and Wickrema A (2003) The hSK4 (KCNN4) iso-
form is the Ca2+-activated K+ channel (Gardos channel) in human red blood cells. Proc Natl Acad Sci U S 
A 100:7366-71
18. Hug BA, Wesselschmidt RL, Fiering S, Bender MA, Epner E, Groudine M and Ley TJ (1996) Analysis of 
mice containing a targeted deletion of beta-globin locus control region 5’ hypersensitive site 3. Mol Cell 
Biol 16:2906-12
19. Lu SJ, Rowan S, Bani MR and Ben-David Y (1994) Retroviral integration within the Fli-2 locus results in 
inactivation of the erythroid transcription factor NF-E2 in Friend erythroleukemias: evidence that NF-E2 is 
essential for globin expression. Proc Natl Acad Sci U S A 91:8398-402
20. Luo Q, Ma X, Wahl SM, Bieker JJ, Crossley M and Montaner LJ (2004) Activation and repression of inter-
leukin-12 p40 transcription by erythroid Kruppel-like factor in macrophages. J Biol Chem 279:18451-6
21. Nuez B, Michalovich D, Bygrave A, Ploemacher R and Grosveld F (1995) Defective haematopoiesis in fetal 
liver resulting from inactivation of the EKLF gene. Nature 375:316-8
22. Ouyang L, Chen X and Bieker JJ (1998) Regulation of erythroid Kruppel-like factor (EKLF) transcriptional 
activity by phosphorylation of a protein kinase casein kinase II site within its interaction domain. J Biol 
Chem 273:23019-25
23. Patrinos GP, de Krom M, de Boer E, Langeveld A, Imam AM, Strouboulis J, de Laat W, Grosveld FG (2004) 
Multiple interactions between regulatory regions are required to stabilize an active chromatin hub. Genes 
Dev 18:1495-509.
24. Perkins AC, Peterson KR, Stamatoyannopoulos G, Witkowska HE and Orkin SH (2000) Fetal expression of 
a human Agamma globin transgene rescues globin chain imbalance but not hemolysis in EKLF null mouse 
embryos. Blood 95:1827-33
25. Perkins AC, Sharpe AH and Orkin SH (1995) Lethal beta-thalassaemia in mice lacking the erythroid 
CACCC-transcription factor EKLF. Nature 375:318-22
26. Rodriguez P, Bonte E, Krijgsveld J, Kolodziej K, Guyot B, Heck AJR, Vyas P, de Boer E, Grosveld F and 
Strouboulis J (2004) Characterization of distinct GATA-1 complexes in erythroid cells: a major role in re-
pression with FOG-1 and MeCP1. submitted
27. Sladek FM, Zhong WM, Lai E and Darnell JE, Jr. (1990) Liver-enriched transcription factor HNF-4 is a 
novel member of the steroid hormone receptor superfamily. Genes Dev 4:2353-65
28. Southwood CM, Downs KM and Bieker JJ (1996) Erythroid Kruppel-like factor exhibits an early and se-
quentially localized pattern of expression during mammalian erythroid ontogeny. Dev Dyn 206:248-59
29. Tewari R, Gillemans N, Wijgerde M, Nuez B, von Lindern M, Grosveld F and Philipsen S (1998) Erythroid 
Kruppel-like factor (EKLF) is active in primitive and definitive erythroid cells and is required for the func-
tion of 5’HS3 of the beta-globin locus control region. Embo J 17:2334-41
30. Tolhuis B, Palstra RJ, Splinter E, Grosveld F and de Laat W (2002) Looping and interaction between hyper-
sensitive sites in the active beta-globin locus. Mol Cell 10:1453-65
Chapter five
96
31. Trimborn T, Gribnau J, Grosveld F and Fraser P (1999) Mechanisms of developmental control of transcrip-
tion in the murine alpha- and beta-globin loci. Genes Dev 13:112-24
32. Tsai SF, Martin DI, Zon LI, D’Andrea AD, Wong GG and Orkin SH (1989) Cloning of cDNA for the major 
DNA-binding protein of the erythroid lineage through expression in mammalian cells. Nature 339:446-51
33. Vandorpe DH, Shmukler BE, Jiang L, Lim B, Maylie J, Adelman JP, de Franceschi L, Cappellini MD, Brug-
nara C and Alper SL (1998) cDNA cloning and functional characterization of the mouse Ca2+-gated K+ chan-
nel, mIK1. Roles in regulatory volume decrease and erythroid differentiation. J Biol Chem 273:21542-53
34. Vu KB, Ghahroudi MA, Wyns L and Muyldermans S (1997) Comparison of llama VH sequences from 
conventional and heavy chain antibodies. Mol Immunol 34:1121-31
35. Wall L, deBoer E and Grosveld F (1988) The human beta-globin gene 3’ enhancer contains multiple binding 
sites for an erythroid-specific protein. Genes Dev 2:1089-100
36. Weiss MJ, Keller G and Orkin SH (1994) Novel insights into erythroid development revealed through in 
vitro differentiation of GATA-1 embryonic stem cells. Genes Dev 8:1184-97
37. Wijgerde M, Grosveld F and Fraser P (1995) Transcription complex stability and chromatin dynamics in 
vivo. Nature 377:209-13
38. Zhang W and Bieker JJ (1998) Acetylation and modulation of erythroid Kruppel-like factor (EKLF) activity 
by interaction with histone acetyltransferases. Proc Natl Acad Sci U S A 95:9855-60
39. Zhang W, Kadam S, Emerson BM and Bieker JJ (2001) Site-specific acetylation by p300 or CREB binding 
protein regulates erythroid Kruppel-like factor transcriptional activity via its interaction with the SWI-SNF 
complex. Mol Cell Biol 21:2413-22
Summary

Summary
99
Summary
The human body consists of a huge number of cells. At the base of all these cells is one 
fertilized oocyte. By cell divisions the number of cells is increased during development, 
and cells specialize into various types of cells, i.e. muscle, brain and blood cells. Groups of 
specialized cells form the various tissues. DNA contains the blueprint of all cells. By each 
cell division the DNA is duplicated and equally distributed over the two daughter cells. 
Hence, practically all the cells contain identical genetic information. The DNA in each cell 
contains about 25.000 genes. Each gene contains information necessary to produce a par-
ticular protein. These proteins are involved in many processes such as energy metabolism, 
cell composition and gene regulation.
Although all cells contain the same genetic information, they specialize into various cell 
types. For this, the genes are specifically activated or repressed. A tight regulation of the 
genes makes it possible to specialize into a particular type of cell. Transcription factors play 
an important role in this tight regulation of activating or repressing genes. EKLF is such a 
transcription factor. EKLF is mainly expressed in red blood cells. These cells give blood 
its red color. They carry oxygen from lungs to tissues in the body that require the oxygen 
for energy metabolism. Red blood cells are filled with hemoglobin that actually binds the 
oxygen. Each hemoglobin particle consists of two α-globin, two β-globin and four heme 
molecules. The genetic blueprint for the β-globin gene is called the β-globin locus. In the 
mouse, this locus contains four globin genes. Two of them, the embryonic β-globin genes, 
are active during embryonic development of the mice and the other two, the adult β-globin 
genes are activated later in development and stay active during the rest of the lifespan of the 
mouse. Apart from the four β-globin genes, the locus contains regulatory elements. These 
include the Locus Control Region (LCR), and a number of other hypersensitive sites. The 
LCR is required for a proper regulation of the globin genes; in absence of the LCR the genes 
are not activated, and mutations in the LCR can lead to impaired activation. The LCR is 
located relatively far from the genes it controls. However, when a globin gene is active in 
red blood cells, the LCR is physically in close proximity to this gene. In fact, the globin 
locus forms a spatial organization that consists not only of the active gene and the LCR, 
but also of the other hypersensitive sites that are located even further away on both sides 
of the genes. This structure is called the Active Chromatin Hub (ACH). Prior to the stage 
in which the genes are active, a substructure of this ACH is formed. Unlike the complete 
ACH, this substructure does not contain the globin genes and part of the LCR. In Chapter 
4 we show that a similar substructure is found in red blood cells that are EKLF deficient. 
We demonstrated that EKLF is necessary for the completion of the ACH, a requirement for 
activating the genes.
The transcription factor EKLF is necessary for the proper development of red blood cells; 
apart from the regulation of the β-globin genes it regulates also other genes. However, it 
was not known which other genes. To study the genes EKLF activates (or represses), we 
used a culture method with erythroid progenitor cells. These progenitor cells are restricted 
to the red blood cell lineage, but have not yet developed to fully differentiated, hemoglobin-
containing red blood cells. The culture method allows us to culture the cells as progenitors 
or induce them to start their terminal differentiation to red blood cells. We performed this 
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culture technique with normal (wild type) cells, and cells that do not have EKLF. Genes 
that become active in normal cells, but not in cells lacking EKLF apparently require the 
presence of EKLF to become active. In Chapter 3 we describe a number of these EKLF 
dependent genes. We show that EKLF is not required in the progenitor cells, but only in 
the last steps of erythropoiesis. The genes that require EKLF to become active are specific 
for red blood cells and they become active late in their development. The genes we have 
focused on in Chapter 3 are involved in hemoglobin metabolism and in membrane stability. 
Failure of activation of these genes further clarifies the problems that red blood cells have 
in the absence of EKLF. In addition we demonstrated that EKLF activates some genes not 
only in adult red blood cells (definitive cells), but also in red blood cells during embryonic 
development (primitive cells). Lack of activation of these genes caused by absence of 
EKLF disturbs the primitive cells; the hemoglobin metabolism is disorganized and the cell 
membrane appears less stable.
Synoptically, we have shown that EKLF is involved in the spatial organization of the β-
globin locus, and in activating a number of genes that are important for the last steps in both 
primitive and definitive red blood cell differentiation.
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Het menselijk lichaam bestaat uit enorm veel cellen. Aan de basis van al deze cellen staat 
één bevruchte eicel. Tijdens de ontwikkeling vermeerdert het aantal cellen door celdelin-
gen, en cellen specialiseren zich tot verschillende soorten cellen, bijv. spier-, hersen- en 
bloedcellen. Groepen van gespecialiseerde cellen vormen de diverse weefsels. DNA bevat 
de blauwdruk van alle cellen. Voor iedere celdeling wordt het DNA gekopieerd en gelijke-
lijk verdeeld over de twee dochtercellen. Derhalve bevatten praktisch alle cellen identieke 
genetische informatie. Het DNA in iedere cel bevat ongeveer 25.000 genen. Elk gen bevat 
informatie die nodig is om een bepaald eiwit te maken. Deze eiwitten zijn betrokken bij 
vele processen, zoals stofwisseling, opbouw van de cel en genregulatie. Alhoewel alle cel-
len dezelfde genetische informatie bevatten, specialiseren ze zich tot verschillende soorten 
cellen. Om dit te bewerkstelligen worden genen specifiek geactiveerd of onderdrukt. Een 
strikte regulatie van de genen maakt het mogelijk om tot een bepaald soort cel te specialise-
ren. Transcriptie factoren spelen een belangrijke rol in de strikte regulatie van het activeren 
of onderdrukken van de genen. EKLF is zo’n transcriptie factor. EKLF komt voornamelijk 
voor in rode bloedcellen. Deze cellen geven bloed zijn rode kleur. Zij transporteren zuurstof 
van de longen naar de weefsels in het lichaam die zuurstof nodig hebben voor de stofwis-
seling. Rode bloedcellen zijn gevuld met hemoglobine, wat het zuurstof feitelijk bindt. 
Elk hemoglobine deeltje bestaat uit twee α-globine ketens, twee β-globine ketens en vier 
heem moleculen. De genetische blauwdruk voor het β-globine heet het β-globine locus. 
Het β-globine locus in muizen bevat vier globine genen. Twee daarvan, de embryonale 
β-globine genen, zijn actief tijdens de embryonale ontwikkeling van de muis en de andere 
twee, de volwassen β-globine genen worden later in de ontwikkeling actief en blijven actief 
gedurende de levensduur van de muis. Behalve de vier β-globine genen, bevat het locus 
regulerende elementen. Tot deze regulerende elementen behoren de ‘Locus Control Re-
gion’ (LCR) en een aantal andere ‘hypersensitive sites’. De LCR is vereist voor een correcte 
regulatie van de globine genen. Zonder de LCR worden de genen niet geactiveerd, en muta-
ties in de LCR kunnen leiden tot een gebrekkige activiteit. De LCR ligt relatief ver van de 
genen die ze reguleert. Wanneer echter een globine gen in rode bloedcellen actief is, ligt de 
LCR in fysieke nabijheid van dit gen. Sterker nog, het β-globine locus neemt een ruimtel-
ijke organisatie aan waarbij niet alleen het actieve gen en de LCR betrokken zijn, maar ook 
de andere hypersensitive sites, die nog verder aan beide kanten van de genen verwijderd 
liggen. Dit complex wordt de ‘Active Chromatin Hub’ (ACH) genoemd.
Voorafgaand aan de fase dat de genen actief zijn wordt er een incompleet complex van de 
ACH gevormd. Deze verschilt van de complete ACH door de afwezigheid van de globine 
genen en een gedeelte van de LCR. In hoofdstuk 4 laten we zien dat rode bloedcellen zonder 
EKLF een zelfde incomplete structuur hebben. We hebben aangetoond dat EKLF nodig is 
voor de voltooiing van de ACH, een vereiste voor het activeren van de genen.
De transcriptie factor EKLF is nodig voor een correcte ontwikkeling van rode bloed cel-
len; buiten het reguleren van de β-globine genen is het ook betrokken bij de regulatie van 
andere genen. Welke deze andere genen zijn, was echter niet bekend. Om te bestuderen 
welke genen EKLF activeert (of onderdrukt), hebben we een kweek methode gebruikt met 
voorloper cellen van rode bloedcellen. De uitgroei mogelijkheden van deze voorloper cel-
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len is beperkt tot rode bloedcellen, maar ze zijn nog niet ontwikkeld tot volledig gediffe-
rentieerde, hemoglobine bevattende rode bloedcellen. De methode maakt het mogelijk om 
de cellen als voorloper cellen te kweken of om ze aan te zetten tot hun definitieve diffe-
rentiatie tot rode bloedcel. We hebben deze kweek methode toegepast op normale cellen en 
op cellen die geen EKLF hebben. Genen die actief worden in normale cellen, maar niet in 
cellen zonder EKLF hebben EKLF kennelijk nodig om geactiveerd te worden. In hoofdstuk 
3 beschrijven we een aantal van deze EKLF-afhankelijke genen. We laten zien dat EKLF 
niet nodig is in de voorloper cellen, maar slechts in de laatste stappen van de rode bloedcel 
ontwikkeling. De genen die EKLF nodig hebben om actief te worden zijn specifiek voor 
rode bloedcellen en zij worden laat in de ontwikkeling van de cellen geactiveerd. De genen 
waarop we onze aandacht hebben gericht in hoofdstuk 3 zijn betrokken bij het hemoglobine 
metabolisme en de stabiliteit van het membraan. Het niet actief worden van deze genen 
heldert de problemen op die rode bloedcellen hebben als EKLF niet aanwezig is. Verder 
hebben we aangetoond dat EKLF enkele genen niet alleen in volwassen rode bloed cel-
len (definitieve cellen), maar ook in rode bloedcellen tijdens de embryonale ontwikkeling 
(primitieve cellen) activeert. Het niet actief worden van deze genen door de afwezigheid 
van EKLF ont-regelt de primitieve cellen; het hemoglobine metabolisme is ontregeld en de 
cel membraan lijkt minder stabiel.
Samengevat hebben we aangetoond dat EKLF betrokken is bij de ruimtelijke ordening van 
het β-globine locus en bij het activeren van genen die belangrijk zijn in de laatste stappen 
van de ontwikkeling van zowel primitieve als definitieve rode bloedcellen.
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Abbreviations
3C Chromosome Conformation Capture
4-OHT 4-hydroxy tamoxifen
aa amino acid
ACH Active Chromatin Hub
AGM  Aorta Gonad Mesonephros
BFU-E Burst Forming Unit, Erythroid
bp base pair
CBP CREB-binding protein
CD34 Cluster of Differentiation 34
cDNA complementary DNA
CFU-E Colony Forming Unit, Erythroid
CFU-GEMM Colony Forming unit for Granulocytes, Erythrocytes, Macrophages, and Megakaryocytes
CFU-S Colony Forming Unit of the Spleen
ChIP Chromatin immuno-precipitation
CHX Cycloheximide
CKII Casein kinase II
CLP Common lymphoid progenitor
CMP Common myeloid progenitor
CREB cAMP response element-binding protein
CTCF CCCTC-binding factor
Dex Dexamethasone
DMSO Dimethyl Sulfoxide
DNA Deoxyribonucleic acid
DNAseI Deoxyribonuclease I
DRB 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole
E12.5 Embryonic day 12.5
EKLF Erythroid Krüppel-like factor
Endo Endoglin
EPO Erythropoietin
FACS Fluorescence activated cell sorter
GMP Granulocyte monocyte progenitor
HAT Histone acetyl-transferase
HDAC Histone de-acetylase
HPC Hematopoietic progenitor cell
HPFH Hereditary Persistence of Fetal Hemoglobin
HS Hypersensitive site
HSC Hematopoietic Stem Cell
IL-3 Interleukin-3
Lin Lineage
LCR Locus Control Region
MEL Murine erythroleukemia
MEP Myeloid and erythroid progenitor
mRNA messenger RNA
NF-E2 Nuclear Factor-Erythroid 2
NLS Nuclear Localisation Signal
PAS Para-Aortic Splanchnopleura
PCR Polymerase Chain Reaction
RBC Red Blood Cell
Rh Rhodamine
RNA Ribonucleic acid
SCF Stem Cell Factor
TGF-β Transforming Growth Factor beta
TRAP Tagging and recovery of associated proteins
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